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Abstract
Phosphatidylserine (PS) is a naturally occurring phospholipid nutrient that is 
predominantly found in the membrane o f  cells. The biochemical actions o f  PS have 
been demonstrated to include; for example: (1) regulation o f  calcium uptake (Floreani 
et al., 1991); (2) stimulation o f  ATPase activity (Tsakiris and Deliconstantinos, 1984); 
and (3) activation o f different Protein Kinase-C (PKC) isoforms (Kaibuchi et al., 
1981). Previous research has shown that supplementation with 800 m gday'1 o f bovine 
cortex-PS (BC-PS) for 10 days attenuated the adrenocorticotrophin and cortisol 
responses to intermittent exercise (Monteleone et al., 1992). Unfortunately, the 
possible risk o f infectious diseases has rendered BC-PS as an unsuitable supplement; 
however, PS derived from soybean (S-PS) has emerged as a safe alternative (Blokland 
et al., 1999). To date, few studies have evaluated the actions o f  S-PS during exercise; 
consequently, the current study aimed to investigate the effects o f S-PS on exercise 
capacity during intermittent cycling (for example, Fahey and Pearl, 1998).
Fourteen healthy young male volunteers, who were matched according to body mass 
and V C>2max values, completed this placebo-controlled, double blind supplementation 
study. Following preliminary assessment and familiarisation sessions, each subject 
completed two main exercise trials separated by 15 ± 1 days. During the ten days 
prior to undertaking the second main trial the subjects received either 750 mg day'1 S- 
PS or a glucose placebo. During the main exercise trials the subjects completed three
10-min stages o f cycling at approximately 45, 55 and 65% V 02max (bouts 1-3, 
respectively) followed by a final exercise bout at 85% V C^ max (bout 4) that was 
continued until volitional exhaustion. The exercise bouts were interspaced with 5-min 
passive rest periods. Breath-by-breath respiratory data (Jaeger Oxycon Pro; Erich 
Jaeger GmbH, Germany) and heart rate data (Polar S810; Polar electro, Finland) were 
continually recorded during both main trials. Venous blood samples and the Exercise 
Induced Feeling Inventory (EFI) (Gauvin and Rejeski, 1993) were collected before 
exercise (pre-exercise), after each exercise bout and on the day following the main 
trial.
The main finding was that exercise capacity, as indicated by time to exhaustion (TTE) 
during bout 4, was 25 ± 6% longer during trial 2 when compared to trial 1 in PS 
(P<0.01) while TTE were not significantly different between supplementation groups 
prior to supplementation (P=0.87). Supplementation had no significant effect on 
serum cortisol responses during intermittent exercise in either supplementation group. 
In addition, feeling states (as indicated on the EFI scale) did not differ following 
supplementation.
This is the first study that has evaluated the effects o f PS supplementation on exercise 
capacity. The mechanism(s) by which PS supplementation delayed the onset o f  
fatigue remain unclear. However, it is plausible that PS might have: (1) increased 
ATPase activity in muscle membrane, and hence maintained ionic balance for longer 
during exercise and; (2) increased calcium availability in the myofibril, prolonged
cross-bridge cycling, therefore delaying fatigue. Further research is warranted to 
investigate the effects o f  S-PS supplementation on physiological function and exercise 
performance.
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1 Introduction
Phosphatidylserine (PS) is a naturally occurring phospholipid nutrient that is 
predominantly found in the membrane o f cells (Blokland et al., 1999). It was first 
isolated and characterised as a constitute o f the cephalin fraction o f  the brain by Folch 
(1942). Structurally, it consists o f 3 different parts: a glycerol backbone, a polar head 
group (which is hydrophilic in nature and contains phosphorus and serine) and 2 
hydrophobic tails, which are fatty acids. The composition o f PS in mammalian tissue 
is relatively small compared to other phospholipids. However, due to the unique 
atomic and electronic topography o f the head piece, the PS molecule is destined for 
preferential association with membrane ‘integral proteins’ which include enzymes, 
receptors and ion channels. It is these PS-protein associations that may be the ultimate 
key to the proposed effects o f PS on a plethora o f physiological functions (Pepeu et 
al., 1996). These functions have been shown to include for example: (1) release o f  
Acetlycholine (ACh) (Davis and Bailey, 1997); (2) activation o f Protein Kinase C 
(Kaibuchi et al., 1981); (3) activation o f Tyrosine Hydroxylase (TH) (Raese et a l ,  
1976); (4) activation o f the sodium-potassium pump ((Na+-K+) pump) (Tsakiris and 
Deliconstantinos, 1984); and (5) increase in total calcium uptake (Floreani et al., 
1991).
Until recently bovine-cortex PS (BC-PS) was the most widely used source o f PS and 
the majority o f the studies that investigated the effects o f PS has on cognitive function 
and endocrine responses to exercise have used PS derived from this source. However,
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BC-PS is now considered unsuitable for human consumption due to the possibility o f  
transferring infectious diseases such as Spongiform Encephalopathy and Creutzfeldt- 
Jakob Disease. Alternative sources o f PS include soybean derived PS (S-PS) and egg 
derived PS (E-PS), which do not posses the health risks that have been associated 
with BC-PS. More recent investigations (for example, Blokland et al., 1999) have 
used S-PS as it has been demonstrated to produce similar effects on cognition as BC- 
PS and the yield o f PS from soybean lecithin is relatively high. In addition, no serious 
side effects have been reported in approximately 100 published clinical investigations 
that have supplemented patients with S-PS and BC-PS. Phopsphatidylserine has been 
shown to have good bioavailability following intravenous, intraperitoneal and oral 
supplementation (Toffano et al., 1987) and it has been shown that exogenous PS is 
efficiently incorporated into the cell membrane o f animal cells (Nishijima et a l ,  
1986). However, the biokinetics o f PS are not clear and, as yet, the wash-out period o f  
PS in the human body is not known; consequently, the interpretation o f cross-over 
study designs may be difficult.
The effect o f PS supplementation on the ageing brain has been extensively 
researched. The majority o f this research has been carried out using BC-PS and the 
available evidence suggests that PS can positively influence higher brain functions 
with subjects who are experiencing cognitive decline (for example, Cenacchi et al., 
1993) and subjects that were considered to have normal cognitive function (for 
example, Benton et al., 2001). However, the limited research that has been completed 
on the effects that S-PS supplementation has on cognitive function has produced
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equivocal findings. Monteleone et al. (1992) demonstrated that oral supplementation 
with 800 mg day'1 o f BC-PS for 10 days significantly attenuated ACTH and cortisol 
responses to intermittent exercise. In addition, Fahey and Pearl (1998) orally 
administered 800 mg day'1 o f S-PS for 14 days to 12 well familiarised subjects during 
a resistance training programme that was designed to promote overtraining. They 
reported that S-PS improved subjective ratings o f well-being, decreased perceived 
muscle soreness and reduced cortisol concentrations after training.
Fatigue during high intensity exercise (at exercise intensities above anaerobic 
threshold) is probably associated with increases in lactate levels leading to a decrease 
in pH in the blood and the working muscle (Westerblad et al., 2002) and the 
breakdown o f phosphacreatine (PCr) to inorganic phosphate (Pj) (Westerblad et al., 
2002). Therefore, the ability o f PS to stimulate ACh release, activate the Na+-K+ 
pump and increase total calcium uptake may act to prolong the time to fatigue. In 
addition, the effects o f PS on the endocrine response to exercise may contribute to an 
increase in exercise capacity and performance by positively increasing the feeling 
states o f subjects. Furthermore, to date, no data have been published to evaluate the 
effects o f PS supplementation during high intensity exercise.
The aims o f the study were to examine the effects o f supplementation with 750 
mg day'1 o f S-PS for 10 days on the neuroendocrine, cardiorespiratory and 
psychological responses to intermittent exercise in active young males. Also, the final
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bout o f exercise, which was continued to exhaustion, was intended to evaluate the 
effects o f S-PS on exercise capacity during high intensity exercise.
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2 Review of Literature
2.1 Phosphatidylserine within the Cell Membrane
2.1.1 Organisation and Function of the Cell Membrane
The cell membrane is essential for the function o f most if  not all-living organisms. 
Bloom et a l  (1991) offered a mechanical description o f the membrane as “a material 
with very small thickness in comparison with its radii o f  curvature, which separates 
two adjacent liquid-like domains and supports the stresses created by the embedding 
medium”. In addition to the many specific functions performed by the cell membrane, 
Yeagle (1987) identified four main generic functions. These were described as: (1) 
maintaining transmembrane gradients; this involves creating and maintaining a 
concentration gradient from one side o f the membrane to the other; (2) the 
organisation o f enzymes into a complex; (3) the control o f enzyme activity within the 
cell; and (4) their use as substrates; the components o f  the membranes may be 
required for use in a specific reactions.
Located within the cell membrane are lipids. These are a diverse group of  
heterogeneous biomolecules that are insoluble in water, but soluble in non-polar 
substances such as chloroform, hydrocarbons or alcohols (McKee and McKee, 1999). 
The functions o f lipids include: (1) energy storage; (2) protective or water proofing;
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and (3) the delivery chemical signals. Their composition varies considerably as 
organelles and membranes having to fulfil a wide variety o f functions. The 
concentrations o f  lipids in the cell membrane range from 80% in myelin to 
approximately 25% in mitochondria (Gurr and Harwood, 1991). Lipids can be 
classified into the following classes: (1) fatty acids; (2) triacylglycerols; (3) wax 
esters; (4) phospholipids; (5) sphingolipids; and (6) isoprenoids.
2.1.2 Structure of Phospholipids
Phospholipids are the major component found in the cell membrane. In the living 
organism the primary role o f the phospholipid is to maintain the structure in the cell 
membrane. All Phospholipids are amphipathic molecules and therefore, despite their 
structural differences, all contain hydrophobic and hydrophilic domains (McKee and 
McKee, 1999). The hydrophobic domain is composed largely o f the hydrocarbon 
chains o f fatty acids while the hydrophilic domain (polar head group) contains the 
phosphate and other charged or polar groups. There are two types o f phospholipids 
known as phosphoglycerides and sphingomelins. Phosphoglycerides contain glycerol, 
fatty acids, phosphate and an alcohol (for example serine, choline and glycerol). The 
simplest form o f a phosphoglyceride is phosphatidic acid, which is the precursor for 
all the other phosphoglyceride molecules (McKee and McKee, 1999). It is composed 
of glycerol-3-phosphate that becomes esterfied with two-fatty acids. The molecule is 
then classified according to which alcohol group becomes esterfied to the phosphate 
group. For example, if  it is the alcohol serine that becomes esterfied then the molecule
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is called phosphatidylserine (PS), other phospholipids include 
phosphatidylethanolamine (PE), phosphatidylcholine (PC), diphosphatidyglycerol 
(dPG) and phosphatidylinositol (PI).
2.1.3 Structure of Phosphatidylserine
Phosphatidylserine is a naturally occurring phospholipid that was first isolated and 
characterised as a constituent o f the cephalin fraction o f the brain by Folch (1942). 
Structurally, PS consists o f 3 different parts: a glycerol backbone (which forms the 
centre o f the molecule) a polar head group (which contains phosphorus and another 
chemical subgroup serine) and 2 hydrophobic tails each o f which are fatty acids 
(Figure 2.1). The unique atomic and electronic topography o f the hydrophilic head 
piece o f the PS molecule destines it for a preferential association with membrane 
‘integral proteins’ which include enzymes, receptors and ion channels that insert deep 
into the membrane.
PS is present in the biological membranes o f all animals, higher plants and micro­
organisms. Table 2.1 shows the phospholipid composition o f various mammalian 
tissues. The % concentration o f PS in the phospholipids pool varies in human tissue; 
skeletal muscle (3%), heart (3%) and in the brain where it is most concentrated (10%) 
(Diagne et al., 1984).
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Table 2.1 The lipid composition in a variety o f  human tissues (adapted from 
Cevc, 1993)
Tissue Phospholipid Composition (% o f lipid Phosphorus)
PC PE PI PS SM
Brain 34 13 3 11 14
Heart 22 14 4 3 6
Liver 45 28 7 4 7
Testis 39 16 5 6 11
Skeletal muscle 48 26 9 3 4
Erythrocytes 31 19 1 13 24
Blood Plasma 77 2 1 0 15
PC: phosphatidycholine; PE: phosphatidyethanolamine; PI: phosphatidylinositol; PS: 
phopsphatidylserine; SM: sphinomyelin.
PHOSPHATE
GLYCEROL
Figure 2.1 Schematic diagram depicting the structure o f Phosphatidylserine, 
showing the glycerol backbone, the polar head group (consisting o f  
phosphate and serine) and the hydrophobic tails. Adapted from 
McKee and McKee (1999)
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Phosphatidylserine is located mainly in the inner leaflet o f the cell membrane which is 
typical for phospholipids containing an acidic head group. It is this acidic head group 
that is responsible for PS having the tendency to associate with membrane proteins.
2.1.4 Functions of Phosphatidylserine
Phospholipids are not merely structural components o f membranes, they are directly 
and actively involved in many cell membrane functions. Even though it is proteins 
that activate most membrane functions such as ion pumps, transport molecules, 
enzymes and receptors, they all depend on the phospholipid matrix to function 
correctly (McKee and McKee, 1999). All phospholipids, including PS, play an 
important role in the membrane o f cells. Their unique structural properties influence 
individual membrane proteins that in turn regulate functions at the cellular level. 
Phosphatidylserine carries a negatively charged amino headgroup which tends to 
associate preferentially with adenosine triphosphatase (ATPase), kinases, receptors 
and other key membrane proteins (McKee and McKee, 1999). These specific PS- 
protein associations may be the ultimate key to the proposed global effects o f PS on 
the brain as a whole (Pepeu et al., 1996). Phosphatidylserine has many important 
functions in the cell membrane which have been demonstrated to include: (1) release 
of Acetylcholine (Vannucchi and Pepeu, 1987; Vannucchi et al., 1990; Casamenti et 
al., 1991); (2) activation o f Protein Kinase C (PKC) (Takai et al., 1979; Wrenn et al., 
1980; Kaibuchi et al., 1981); (3) activation o f Tyrosine Hydroxylase (TH) (Raese et 
al., 1976); (4) activation o f the sodium-potassium (Na+-K+) pump (Specht and
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Robinson, 1973; Tsakiris and Deliconstantinos, 1984); and (5) increase total calcium 
uptake (Floreani et al., 1991).
Acetylcholine (ACh) is a neurotransmitter that is released by neurons o f  the motor 
nerve cells to change the permeability or other properties o f another cell membrane. 
Release o f ACh from the synaptic terminal alters the permeability o f the sarcolemma 
and triggers the contraction o f the muscle fibre. Phosphatidylserine has been 
demonstrated to restore ACh levels in ageing rats (Vannucchi and Pepeu, 1987). The 
authors pre-treated aged cortical slices from rats with 15 mg kgBW '1 and found that 
PS restored ACh levels to that o f younger rats. Also Vannucchi et al. (1990) showed 
that PS stimulated ACh release in both young and aged rat cortical slices when dosed 
15 mg kg BW'1 intraperitoneally (i.p.) daily for one week. Similarly, Casamenti et al. 
(1991) demonstrated that ACh release was increased though supplementing rats with 
15 mg kg BW'1 o f PS i.p daily for 8 days. They suggested that this chronic PS 
treatment improved ACh release by increasing availability o f choline for ACh 
synthesis. There are a number o f studies that demonstrate that PS increase ACh levels 
(For example Vannucchi et al., 1990), especially in aged rat cortical slices; however, 
these studies have been completed using animal models and care should be taken 
when extrapolating these data to humans.
Protein kinase C are a group o f second messenger enzymes, associated with the 
cytoplasmic face o f the cell membrane, that are stimulated by calcium and/or 
phospholipids (Silverthom, 2001). Protein Kinase C complexes play a pivotal role in
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mediating cellular responses to extracellular stimuli. They also catalyse the 
phosphorylation o f a number o f target neuronal proteins which control a number of  
functions in the cell membrane such as growth and cellular differentiation. Neuronal 
proteins, such as PKC, are also thought to regulate neurotransmitter release by way of  
controlling the hormone receptor-transduction mechanisms (Canonico and 
Scapagnini, 1989). Wrenn et al. (1980) demonstrated that the calcium dependent 
phosphorylation o f a number o f proteins, including PKC, in the cytosol o f the rat or 
guinea pig cerebral cortex was profoundly stimulated by PS. Takai et al. (1979) 
demonstrated that PS was the sole phospholipid to be effective in activation of 
calcium activated PKC. Furthermore, Kaibuchi et al. (1981) demonstrated that PS 
plays a positive role in activating this unique protein kinase.
Tyrosine hydroxylase is the rate limiting enzyme involved in the synthesis o f  
dopamine and noradrenaline. Raese et al. (1976) showed that the addition o f PS to a 
incubation mixture purified from rat brain striatal synaptosomal fraction strongly 
activates TH. It is possible that an inactivation o f TH is involved in the 
pathophysiology o f psychiatric disorders and associations have been reported for TH 
gene markers in mood disorders. Serretti et al. (1998) showed TH variants may be 
related with depressive symptomatology in subjects affected by mood disorders. 
Therefore, an increase in TH activation would lead to an increase in dopamine. 
Dopamine has long been associated with euphoria, desire and motivation. Moreover,
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dopamine disorder or imbalance can cause memory and cognitive loss as well as 
difficulty with problem solving (Diehl and Gershon, 1992; Ashby et al., 1999).
The Na+-K+ stimulated enzyme ATPase is an integral membrane enzyme that is found 
in cells o f all higher organisms. It is the enzyme responsible for the ATP-dependent 
transport o f sodium (Na+) and potassium (K+) across the cell membrane (known as the 
Na+-K+ Pump). It is a multi unit enzyme that moves three Na+ out o f  the cell along 
with two K+ in to the cell at the expense o f hydrolysed ATP (Westerblad et al., 1991). 
This gradient needs to be maintained between the interior and the exterior o f the cell 
for a number o f reasons that include facilitated diffusion across the cell and 
maintenance o f the action potential. The net result o f intracellular ionic concentration 
changes during exercise will be a reduction in the intracellular strong ion difference 
and consequently a marked rise in intracellular hydrogen ion concentration 
(McKenna, 1992). This intracellular acidosis in humans has been linked with 
impairment o f regulatory and contractile protein function, calcium (Ca2+) regulation 
and metabolism. PS has been demonstrated to increase Na+-K+ stimulated ATPase. 
Tsakiris and Deliconstantinos (1984) demonstrated that synaptosomal plasma 
membrane from dogs treated with incubated PS showed an increase in Na+-K+ 
stimulated ATPase. Phosphatidylserine has not only been shown to increase Na+-K+ 
stimulated ATPase in the plasma membrane from dog, but it has also been 
demonstrated to increase the amount o f ATPase in rabbit kidney preparations 
stimulated with small concentrations o f PS (Specht and Robinson, 1973).
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Phosphatidylserine has been shown to increase total Ca2+ uptake in rat brain 
synaptosomes (Floreani et al., 1991). These authors incorporated PS vesicles into rat 
brain synaptosomes in varying amounts. They demonstrated that potassium 
depolarisation-induced-calcium uptake was stimulated at low amounts o f incorporated 
PS (lower than 0.1 pmol PS mg protein"1). At concentrations o f PS above 0.1 pmol 
PS mg protein"1, an increase in either Na+/Ca2+ exchange activity or passive Ca2+ 
influx was evident and these accounted for the increase in total Ca2+ uptake by 40 and 
60%, respectively. In short, this demonstrates that PS modifies Ca2+ uptake upon 
incorporation into the membranes o f rat brain synaptosomes.
2.2 Phosphatidylserine as a Nutritional Supplement
2.2.1 Sources of PS
Phosphatidylserine can be derived for nutritional supplementation from several 
sources. Until recent times bovine-cortex PS (BC-PS) has been the most widely used 
source o f PS (Blokland et al., 1999). However, BC-PS is now considered unsuitable 
for human use due to the possibility o f transferring infectious diseases, such as Bovine 
Spongiform Encephalopathy (BSE) and Creutzfeldt-Jakob disease (CJD).
Other sources o f PS include soybean derived PS (S-PS) and egg derived PS (E-PS). 
These sources o f PS are free from the health risks posed by BC-PS. 
Phosphatidylserine derived from these sources have a similar biochemical structure
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with respect to the glycerol moiety and serine head group; however, the fatty acid 
components are different in S-PS, being virtually devoid o f arachidonic and decosa 
hexenoic acid (Blokland et al., 1999).
Approximately 100 clinical studies investigating the effects o f both BC-PS and S-PS 
supplementation in humans have been published and to date no serious side effects 
have been reported. Cenacchi et al. (1993) retrospectively reviewed the results o f  
common haematological variables taken from 130 subjects who underwent oral 
treatment with PS (300mg day'1 o f BC-PS daily for 60 days) in an effort to explore 
the biochemical tolerability o f PS. Even though significant reductions in uric acid and 
liver alanine aminotransferase levels were noted, these were considered clinically 
negligible.
Blokland et al. (1999) examined the behaviour o f rats after treatment with a daily 
dose o f 15 mg kg BW'1 PS derived from S-PS, E-PS, BC-PS or a placebo. It appeared 
that the cognition enhancing effects o f S-PS were not different from those o f BC-PS; 
however, those treated with E-PS did not differ from the placebo group. Therefore, it 
was concluded that S-PS, but not E-PS, may have comparable effects on cognition as 
BC-PS. The authors stated that the differences between S-PS and E-PS were 
unexpected, due to the similar molecule composition o f S-PS and E-PS. They 
speculated that E-PS may have lost bioactivity due to breakdown o f the bioactive 
compound during processing or storage.
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2.2.2 Digestion and Absorption of Phosphatidylserine
Even though PS supplementation has been shown to have good bioavailability, it is 
currently unclear whether exogenous PS is able to reach the inner membrane o f  cells 
and exert the same biochemical effects as endogenous PS; these effects include the 
activation o f PKC, increasing ATPase activity, activating TH and facilitating calcium 
uptake. It has been demonstrated that exogenous PS can be efficiently incorporated 
into cultured Chinese hamster ovary cells and then utilized for membrane biogenesis 
(Nishizuka, 1986). PS has also been shown to be incorporated into olfactory 
epithelium by incubating these epithelium with a PS-suspension containing 
radiolabeled PS (Taniguchi et al., 1994). Also, when I4C- labelled PS was directly 
administered into the cerebral ventricles o f rats, the hypothalamus strongly attracted 
the isotope label (Toffano et al., 1987). It has been demonstrated that intravenously 
(i.v) injected PS vesicles were rapidly removed from plasma since they are taken up 
by macrophages and internalised by lymphocyte and endothelial cells (Ponzin et al., 
1989). These actions show that exogenous PS directly interacts with cell membranes.
Administration o f radiolabelled PS (20 mg kg BW'1) by three different routes (i.v) 
(i.p) and oral was investigated in rats by Toffano et al. (1987). These authors found 
that, following oral administration, the appearance o f the isotope label in the blood 
increased slowly and consistently over a 24-hour period. When the same dose was 
administered intravenously, the concentrations o f PS in the blood were halved very 
rapidly (2-8 mins). This rapid clearance from the blood is probably reflective o f  tissue
16
uptake across a range o f organs which appeared to be saturated within 10 min. 
Furthermore, it has been demonstrated that when mice were intravenously injected 
with 20 mg kg'1 BW of PS, the rapid clearance from the blood coincided with uptake 
by both the liver and the brain (Toffano et al., 1987).
Twenty min after i.v. administration with 20mg kg'1 BW o f 14C-Labelled PS in mouse 
brain tissue 90-95% o f the isotope labelled material was recovered from the brain and 
was identifiable on thin-layer chromatography as PS. This equated to about 0.25% o f  
the injected dose, a significant proportion when comparing this to the fact that a 
mouse brain represents 1.5% o f total body weight (Toffano et al., 1987). Examination 
of separate brain areas showed that most radioactivity was present in the cortex, 
hypothalamus and hippocampus.
From the limited data available regarding the pathway o f PS into the body, it seems 
that PS has good bioavailability via i.p, i.v and oral routes. Currently there is limited 
information on the uptake and bioavailability o f PS following long-term 
supplementation in humans; however, the pharmacological effects o f exogenous PS 
suggest that PS is able to reach the brain and other tissue areas. Even though the 
amount o f PS incorporated may be small, a number o f studies have demonstrated that 
exogenous PS, from oral route or injection, can have psychological and physiological 
effects that include enhanced cognitive function (Cenacchi et al., 1993) and a 
reduction in cortisol concentrations following acute stress (Monteleone et al., 1992).
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In fact, most o f  the published clinical data following PS supplementation has utilised 
the oral route. These studies have shown that PS has varying pharmacological effects 
mainly on cognitive function. Doses o f PS that have been shown to have positive 
effects have ranged from long term moderate dosing (For example, 300 mg day'1 for 
up to 3 months; Cenacchi et a l ., 1993) to higher short term dosing (For example, 800 
mg day'1 for 10 days; Monteleone et al ., 1992). It may be that only a small amount o f  
exogenous PS actually reaches its target. However, it is probable that PS accumulates 
in the brain and other membrane sites through long term moderate and higher short 
term supplementations (Pepeu et al., 1996). The plausible accumulation effect could 
explain the persistence o f some o f the effects o f PS supplementation even after 
treatment has ended (Engel et al., 1992). In this study, 33 patients with mild 
degenerative dementia were dosed for 8 weeks with 300 mg day'1 o f PS in a cross­
over study. The subjects showed improvements that continued over the 8-week 
washout period. This finding and the lack o f available data on the appropriate washout 
period o f PS suggests that care must be taken when interpreting published research 
that utilised cross-over designs.
2.2.3 Phosphatidylserine Supplementation and Cognitive Function in 
Humans
The effects o f  PS supplementation on the ageing brain have been extensively 
researched. Most o f  the studies that have been well controlled suggest that dietary
18
supplementation with PS can play an important role in the support o f  mental functions 
in the aging brain. Among the clinical trials conducted with PS, most were undertaken 
with patients who had experienced measurable losses in memory, judgment, abstract 
thought, and other higher mental functions; therefore, these findings may have limited 
relevance when considering the ‘normal population’. Following searching in Pubmed, 
Web o f Knowledge, Science Direct and Google Scholar using the following key 
words: PS, cognitive function, mood, and brain some activity on PS and various 
words including cognitive function, mood, double-blind and placebo, 13 double-blind 
and placebo controlled clinical trials were identified (Table 2.2). In addition 
approximately 100 studies were identified that investigated these areas but used 
inferior study designs and therefore were discarded. O f the studies that were more 
tightly controlled the findings strongly suggest that PS supplementation has positive 
effects and psychological and cognitive function. A double-blind study that was 
carried out by Cenacchi et a l  (1993) investigated cognitive function in geriatric 
patients. They found that supplementation with 300 mg-day'1 BC-PS for six months 
statistically improved cognitive and behavioural patterns when compared with the 
placebo group. Maggioni et a l  (1990) provided 300 mg-day'1 o f BC-PS for 30 days to 
10 elderly women with depressive disorders and reported that consistent 
improvements in depressive symptoms, memory and behaviour were observed. The 
only cross-over study that has indicated a wash out period following supplementation 
with PS was carried out by Engel et a l  (1992). They supplemented thirty-three 
patients with mild degenerative dementia with 300 mg-day'1 o f BC-PS. 
Supplementation lasted 8 weeks and was followed by an 8-week washout period.
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Clinical global improvement ratings were significantly improved under the PS 
condition when compared to the placebo condition and this improvement carried on 
into the continuing washout period. If the positive affects o f PS are carried over into a 
washout period and the duration o f this period is unknown for PS, then the 
conclusions drawn from cross-over studies are difficult to interpret. Therefore, BC- 
PS, when supplemented for a range o f time periods, has been demonstrated to 
improve cognitive and behavioural patterns in subjects who have shown depressive 
symptoms in these areas.
Not only has PS been shown to improve cognitive function; interestingly, 
supplementation has also been shown to boost electroencephalogram (EEG) rhythms 
(Rosadini et al., 1990). These authors administered 25, 50 or 75 mg o f BC-PS i.v. to 
eight healthy volunteers. It was noted that the highest dose o f PS boosted the average 
alpha rhythm by 15-20% without any detectable side effects. Moreover, alpha 
rhythms are often found to be attenuated in the ageing and people with cognitive 
decline (Rosadini et al., 1990). This study was carried out on what would be 
considered a ‘normal’ population and the results suggest that supplementation o f BC- 
PS administered intravenously, increased the EEG alpha rhythm. The alpha rhythm as 
detected by EEG, is considered a direct measure o f brain function and increases in 
alpha rhythm changes have been associated with improvements in general mood state 
(Kumano etal., 1996).
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To date there have been very few human studies that have looked at the effects o f S- 
PS on various psychological and cognitive functions. However one such study that 
uses S-PS and is considered to employ a strong study designs has produced results 
that are in conflict with the majority o f the previous research on PS. Jorissen et a l  
(2001) supplemented 120 elderly subjects who fulfilled the criteria for age-associated 
memory impairment (AAMI). These subjects were allocated in a random order to 
receive either 300, 600 mg S-PS or placebo for 12 weeks. Assessments o f learning 
and memory, choice reaction time, planning and attention functions were carried out 
at the beginning o f supplementation, after 6 and 12 weeks and 3 weeks post­
supplementation. No significant differences were found in any o f  the outcome 
variables between the treatment groups. The reasons for the ineffectiveness o f S-PS to 
show positive findings are unclear; however, it may be that the word list, which was 
the main outcome tested, was not capable o f showing any true cognitive differences 
between the groups and only ‘some’ o f the 120 elderly fulfilled the criteria for 
cognitive decline. Therefore, this study demonstrated that S-PS did not affect memory 
recall in elderly patients and may not o f evaluated cognitive function.
There have been 2 studies to date which have investigated the effects o f  S-PS on 
subjects who are not experiencing some sort o f cognitive decline, one o f which 
investigated feeling states and the other mood and heart rate in response to stress. 
Benton et al. (2001) studied the effects o f S-PS on feeling states in a ‘normal’ young 
student population. These authors supplemented 22 subjects with 300 mg-day’1 o f S- 
PS for 30 days while a further 26 subjects received a suitably matched placebo.
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Following supplementation with S-PS, those who were defined as having a more 
neurotic personality showed statistical significant improvements in feeling clear­
headed, composed and confident, feeling energetic and elated when faced with the 
acute stressor o f performing a demanding mental arithmetic task. During this study 
none o f subjects supplemented with PS guessed that they had taken the supplement; 
therefore, suggesting that the double blind procedure was not compromised. 
Hellhammer et a l  (2004) investigated the influence o f soy lecithin phosphatidic acid 
and PS complex (PAS) supplementation on mood and heart rate when faced with an 
acute stressor. Four groups o f 20 subjects were treated with 400, 600 or 800 mg PAS 
or placebo for 3 weeks prior to completing the Trier Social Stress Test (TSST). They 
demonstrated that supplementation with 400 mg PAS blunted serum ACTH and 
cortisol concentrations, and salivary cortisol responses to the TSST, while the placebo 
group showed the expected increase in distress post TSST. Interestingly, neither the 
600 and 800 mg supplementation groups showed the positive effects demonstrated in 
the 400 mg group.
In summary, the majority o f the available evidence available suggests that PS 
supplementation (provided in varying forms o f administration and different dosing 
regimes) can positively affect cognitive and higher brain functions in subjects with 
cognitive decline. In addition, it seems that not only does it improve these 
abnormalities, it also has positive effects on mood, EEG alpha rhythm and endocrine 
response in subjects that were considered to have normal cognitive function. 
However, there are a limited number o f studies that have been carried out using S-PS
24
and further research needs to be carried out with S-PS to confirm the effects 
supplementation has on cognitive function.
2.2.4 Phosphatidylserine Supplementation and its Effects during 
Exercise
To date there have been three peer reviewed published studies that have examined the 
effects o f PS supplementation on humans during exercise (Table 2.3). Monteleone et 
al. (1990) studied the effects o f PS on neuroendocrine responses to physical stress in 
humans. These authors supplemented eight healthy men who did not participate 
regularly in any kind o f sport on three separate occasions with PS or placebo. Twenty 
min following i.v. administration (50, 75 mg o f BC-PS and volume-matched placebo) 
the subjects completed three six-min bouts o f exercise on a cycle ergometer at 
different workloads (1.5, 2.0, and 2.5 W kg BW'1, respectively) interspaced with 1- 
min rest periods. Venous blood samples were collected prior to i.v. injection, 10 min 
following i.v. injection, at the end o f each workload and then 20 and 60 min after the 
completion o f exercise. They showed that the physical stress caused significant 
increases in plasma ACTH and cortisol concentrations and that cortisol peaked 20 min 
prior to the end o f  exercise. These responses were attenuated in both BC-PS treatment 
groups. Similarly, Monteleone et al. (1992) supplemented nine healthy inactive 
subjects, orally with 800 mg-day'1 o f BC-PS, 400 mg-day'1 o f BC-PS and a suitably 
matched placebo for 10 days.
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During this study the same exercise and venous sampling protocols were used as 
employed during the groups previous study (Monteleone et al., 1990). The exercise 
induced increase in ACTH and cortisol concentrations were significantly blunted by 
800 mg-day'1 BC-PS but not by 400 mg-day'1 BC-PS. Therefore, it was concluded that 
the blunting o f the HP A- axis was dose specific and under these conditions 800 
mg-day'1 was required to attenuate the ACTH and cortisol responses to exercise. 
Unfortunately, these authors offered no information about the order of  
supplementation; therefore, it may be possible that the subjects were supplemented, 
with a placebo, then 400 mg-day'1, and finally 800 mg-day'1. If this was the case, then 
accumulation o f PS in the tissues may well have occurred and consequently this 
accumulation may have lead to the dose response reported for ACTH and cortisol 
response. Both Monteleone et al. (1990) and Monteleone et al. (1992) employed 
intermittent progressive exercise with absolute exercise intensities; therefore, the 
subjects were working at varying relative exercise intensities which could lead to 
different endocrine responses between subjects depending upon subject fitness. In 
support o f this statement, Luger et al. (1987) reported that active subjects have been 
shown to have a lower cortisol response when compared with sedentary individuals 
exercising at equivalent absolute and relative exercise intensities. Therefore the large 
ACTH and cortisol responses to exercise reported by Monteleone et al. (1990) and 
Monteleone et al. (1992) probably reflected the training status o f the subjects. By 
having larger responses o f ACTH and cortisol to exercise any effect that PS may have 
on the endocrine system may be easier to indentify.
27
Fahey and Pearl (1998) orally administered 800 mg-day'1 o f  S-PS for 14 days to 
twelve resistance trained subjects during a resistance exercise induced over training 
regime. Subjects taking the S-PS reported a significantly greater sense o f well-being 
during the 2-week training regime and a decreased perception o f muscle soreness 
when compared with the placebo group. Cortisol concentrations were also reduced 
after training; furthermore, the authors suggested that this reduction in cortisol was 
not sufficient to change vital cortisol functions such as gluconeogenesis. A cross-over 
design was used during this study and as there is no information available on the 
washout period o f PS an accumulation effect o f PS could occur if  subjects were 
supplemented with PS followed by the placebo. However, these results support the 
conclusions o f Monteleone et a l  (1990) and Monteleone et al. (1992) who suggested 
that PS supplementation suppressed the HPA-axis response to exercise.
In summary, these findings must be considered somewhat preliminary due to the 
small quantity o f published data; however, findings are consistent with an influence o f  
PS on brain function. From these studies it seems that PS supplementation, both in the 
form o f BC-PS and S-PS, reduces blood cortisol concentrations during exercise. In 
addition, 800 mg-day'1 o f S-PS for 14 days increased subject well-being and reduced 
perception o f muscle soreness. Even though both endocrine responses and mood have 
been shown to be affected by PS, to date there are no peer-reviewed studies that have 
examined the effects o f PS supplementation on exercise performance or exercise 
capacity. Furthermore, controlled trials are needed to investigate the effects o f PS 
supplementation on the HPA -  axis and mood during exercise on a trained population.
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2.3 Physiological Responses to Exercise
2.3.1 Hormonal Responses to Exercise
Stress generated by a significant change from the ‘normal’ psychological and 
physiological state causes the hypothalamus to release corticotrophin-releasing 
hormone (CRH). This generic response has been demonstrated to be initiated during 
changes in self-rated emotional states (Gerra et al., 1998), other psychological 
stressful situations (Aguilera, 1998) and physical activity (Davies and Few, 1973). 
Thus, cortisol has been used as a marker o f overall stress and is sometimes called a 
‘stress hormone’. It is the stimulation o f the hypothalamus and the release o f CRH 
which leads to a change in the hypothalamic-pituitary-adrenal (HPA) axis. Activation 
o f the HPA axis stimulates the anterior lobe o f the pituitary gland to release 
Adrenocorticotrophin hormone (ACTH), which upon reaching the adrenal cortex 
causes cortisol to be released.
The glucocorticoids, including cortisol, have been known to increase during 
demanding physical activity for approximately 50 years (Staehelin et a l ,  1955). More 
recently it has been demonstrated that cortisol secretion is dependent on the intensity 
and duration o f exercise (Davies and Few, 1973). These authors demonstrated that 
plasma cortisol concentrations were maintained or decreased at exercise intensities 
below -50%  V 02max on a treadmill; however, at exercise intensities o f 65- 
90% V 02max increases in plasma cortisol concentrations were shown after 10 min of
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exercise. As the exercise intensity approaches anaerobic threshold, the relative 
cortisol increases from baseline (Port, 1991). In addition, during short-term high- 
intensity exercise the blood plasma cortisol response has been shown to increase with 
the intensity o f leg power up to 100% o f maximal leg power on a cycle ergometer 
(Kraemer et al., 1989). Luger et a l  (1987) found that the exercise induced increase in 
serum cortisol concentrations were attenuated in response to a given workload in 
trained subjects when compared to untrained subjects.
Hormones such as cortisol tend to be secreted into the blood in an episodic manner, 
where secretions may be separated by rest periods anywhere between 5 and 30 min 
(Brandenberger et a l , 1984); additionally the body's level o f cortisol in the 
bloodstream displays what is known as a diurnal variation; that is, normal 
concentrations o f cortisol vary throughout a 24-hour period (Edwards et a l , 2001). 
Following sub-maximal treadmill running in moderately trained young men, cortisol 
has been shown to remain elevated for as long as 2 hours after exercise (Kanaley et 
a l , 2001); however, peak cortisol concentrations have been reported to occur at 
approximately 10-40 min post-exercise (Davies and Few, 1973; Monteleone et a l ,  
1990; Monteleone et a l ,  1992; Jacks et a l ,  2002).
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2.3.2 Fatigue during Exercise
Fatigue during exercise has been defined as an inability o f muscle or a group of 
muscles to maintain a required or expected force (Edwards, 1981). Fatigue during 
voluntary muscular contraction is a complex phenomenon and may be caused by 
central nervous factors as well as changes in the peripheral site o f the neuromuscular 
system (Allen, 2004).
Fatigue has been extensively researched; however, the research in this area has tended 
to concentrate on the extremes o f exercise duration and intensity, such as supra­
maximal and endurance exercise. For the purpose o f this review supra-maximal 
exercise has been considered to be any exercise at an intensity above V Chmax, to 
include exercises such as short-sprints or repeated lifting o f heavy weights; whereas 
endurance exercise is considered exercise that exceeds an hour in length o f time. 
There has been relatively little research on the mechanisms o f  fatigue during high- 
intensity exercise; which, for the purpose o f this review was considered to be exercise 
at intensities above the anaerobic threshold but below V 02max- In addition, 
investigators who have studied fatigue have tended to use various stimulation 
schemes which makes it very hard to make direct comparisons between studies 
(Westerblad et al., 1991). Both supra-maximal and high intensity exercise intensities 
cause a large increase in both blood and muscle lactate and both break down glycogen 
at a fast rate, and use large amounts o f  energy. When muscles are worked at high
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work loads, stores o f energy within the muscle are used up at a fast rate and the by­
products o f these reactions accumulate within the working muscle and blood.
Measurements o f  muscle lactate concentrations after exercise have shown that the 
maximum accumulation o f lactate within the muscle occurs at the end o f exercise that 
causes exhaustion in approximately 3-7 min (Maughan and Gleeson, 2004). High 
levels o f  intracellular lactic acid can lead to intracellular acidosis which causes 
intracellular pH to fall, have long been discussed as being a cause o f fatigue 
(Westerblad et al., 2002). Therefore, both supra-maximal efforts and high-intensity 
exercise will cause large amounts o f lactic acid. There have been a number o f studies 
that have shown a link between this decline o f  intracellular muscle pH and the 
reduction o f force or power production (Fabiato and Fabiato, 1978). However, this 
link is coming under question as many studies are concluding the lowering o f pH only 
leads to fatigue in lower temperatures and not the physiological temperatures that are 
found in the human body. Pate et al. (1995) found the reduction in fatigue to be 
minimal at 30°C on skinned rabbit fibres when compared to 10°C.
During supra-maximal intensities the phosphacreatine (PCr) content in the working 
muscle is all or nearly all depleted in a matter o f seconds (Bogdanis et al., 1996). As a 
result o f PCr levels depleted, inorganic phosphate ( P j )  is produced from the 
breakdown o f PCr. Therefore, if  PCr levels are being depleted in the working muscle
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excess inorganic phosphate will be produced, which has been shown to a potential 
cause o f fatigue (Westerblad et a l ,  2002). As exercise intensity drops so does the 
amount o f depletion o f PCr in the working muscle. At intensities o f approximately 80- 
90% V 02max PCr levels have been shown to be depleted by up to as much o f half 
there original resting values (Maughan and Gleeson, 2004); consequently producing 
high-levels o f Pj in the muscle, which would potentially lead to fatigue.
Depending on different variables such as exercise duration/intensity and the muscular 
groups tested and the type o f contractions involved, strength loss with fatigue can 
originate from several sites from the motor cortex through to contractile elements 
(Bigland-Ritchie, 1981; Edwards, 1981; McKay et a l ,  1995). This phenomenon has 
been termed 'task dependency o f muscle fatigue' (Millet and Lepers, 2004). Fatigue 
caused by exercise that occurs at intensities that require intense contraction, 
particularly with large muscle groups have been commonly attributed to what is 
known as peripheral fatigue (Green, 1997). In principle, the site o f peripheral fatigue 
could occur along a number o f sites including the neuromuscular junction, the process 
o f excitation-contraction (E-C) coupling (which involves the activation o f the surface 
membrane), the propagation o f that activation down the T-tubules (which brings the 
activation into the depths o f the cell), the release o f  calcium and, finally, the 
activation o f  the contractile elements involved in the generation o f force and power. 
Therefore; fatigue can be attributed to any number o f mechanisms during this process; 
however, the most probable causes could include: (1) a reduction in neurotransmitter 
release at the neuromuscular junction (Davis and Bailey, 1997); (2) disturbances in
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the ionic changes that may lead to an inability to maintain the membrane potential and 
excitability (Green, 1997); and (3) a failure o f  normal calcium release from the 
sarcoplasmic reticulum (Allen and Westerblad, 2001).
2.3.2.1 Acetlycholine and Fatigue
Each motor neurone activates a group o f muscle fibres and is collectively referred to 
as a motor unit. The chemical messengers, or neurotransmitters, that carry the nerve’s 
excitation message to the muscle at the neuromuscular junction can become impaired 
with intense exercise. One o f the main neurotransmitters in this case is ACh. At the 
neuromuscular junction an action potential causes release o f ACh from the nerve 
ending, and this will cause a local depolarisation in the end-plate area o f the surface 
membrane o f the cell (Westerblad et al., 1991). The local depolarisation will initiate 
the action potential that propagates along the surface membrane. Acetylcholine has 
been shown to be impaired during exercise and any inhibition would result in the 
inability o f local depolarisation and as a consequence o f this the action potential 
would not propagate along the surface membrane. This would lead to the muscle 
fibres being unable to contract, and therefore lead to cessation o f exercise (Davis and 
Bailey, 1997). PS has been shown to increase ACh in rat cortical slices when 
supplemented with PS (Vannucchi and Pepeu, 1987; Vannucchi et al., 1990; 
Casamenti et al., 1991). If this increase in ACh is transferable to humans when 
supplemented with PS, then this increase in ACh could potentially delay the onset o f  
fatigue during intense exercise. Increasing ACh availability during exercise could
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potentially cause local depolarisation to carry on occurring and therefore the action 
potential would still propagate along the surface membrane for an extended period of 
time.
2.3.2.2 Ionic Balance across the Cell Membrane and Fatigue
Fatigue during maximal efforts has also been linked to Na+ and K+ disturbances in 
ionic balance across the cell membrane (Green, 1997). Ionic changes in the cell are 
central to the activity o f a muscle due to the action potential being caused by rapid 
movements o f Na+ and K+ in and out o f the cell (Allen, 2004). Disturbances in these 
ionic balances play an important role in the development o f muscular fatigue (Clausen 
and Nielsen, 1994). As previously mentioned intense muscular contraction is 
accompanied by the anaerobic breakdown of glycogen and PCr whose by products are 
lactate and inorganic phosphate (P j) .  This combined with the increased muscle water 
content, which is distributed in both intracellular and extracellular spaces, modifies 
ionic balance across the cell membrane. Changes in muscle intracellular electrolyte 
concentrations with intense contraction may be summarised as including decreases in 
K+ (6 to 20%), decreases in PCr (up to 70 to 100%), increases in lactate (more than 
10-fold), increases in Na+ (2-fold) and small, variable increases in chloride 
(McKenna, 1992). The net result o f these intracellular ionic concentration changes 
with exercise will be a reduction in the intracellular strong ion difference, with a 
consequent marked rise in intracellular hydrogen ion concentration. This intracellular 
acidosis has been linked with fatigue via impairment o f  regulatory and contractile
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jprotein function, Ca regulation and metabolism. Potassium efflux from the 
contracting muscle cell dramatically decreases the intracellular to extracellular 
potassium ratio, leading to depolarisation o f sarcolemmal and t-tubular membranes. 
During non-steady state incremental exercise up to about 60% V 02max, plasma K+ 
increases proportionally to increases in oxygen consumption; thereafter, it increases 
disproportionately (Paterson et a l , 1990) until the point o f  exhaustion where it can 
reach 8-9 mmol'1 in the arterial blood (Medbo and Sejersted, 1990). These 
transmembrane fluxes, under normal circumstances are counteracted by the Na+ - K+ 
pump, however, during intense muscular stimulation the efficacy o f the Na+ - K+ 
pump may be reduced; consequently these Na+ and K+ ionic shifts transpire (Clausen 
and Nielsen, 1994). Fowles et al. (2002) investigated the hypothesis that reductions in 
(Na+-K+)- ATPase activity are associated with neuromuscular fatigue following 
isometric exercise. These results demonstrated that (Na+-K+)- ATPase activity is 
reduced by sustained isometric exercise in humans from and that this reduction in 
(Na+-K+)- ATPase activity is associated with loss o f cell excitability. If these 
reductions in (Na+-K+)- ATPase activity could be reduce or if  (Na+-K+)- ATPase 
activity could be increased in the cell membrane then potentially fatigue could be 
delayed. PS has been shown to increase (Na+-K+)- ATPase activity in both dog 
synaptosomal plasma membrane (Tsakiris and Deliconstantinos, 1984) and rabbit 
kidney preparations stimulated with small concentrations o f  PS (Specht and 
Robinson, 1973). Therefore, by acting as a buffer, PS could work to minimise these 
disturbances in ions across the cell membrane which are caused by intense exercise.
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2.3.2.3 Calcium and Fatigue
As previously stated anaerobic metabolism in skeletal muscle involves hydrolysis o f  
PCr to Pj.  Inorganic phosphate has been shown to be an important factor in the causes 
o f fatigue during high-intensity exercise (Westerblad et al., 2002) and it has become 
evident in recent years that Pj may affect fatigue by effecting sarcoplasmic reticulum 
Ca2+ handling. Calcium plays an important and complex role in generation o f force 
and power in the muscle and has been linked as a possible cause o f tension decline 
during fatiguing situations such as high intensity short-term exercise (Allen, 2004). 
As a result o f Ca2+ release from the sarcoplasmic reticulum (SR), Ca2+ binds to 
troponin C, causing an interaction between myosin and actin resulting in cross-bridge 
cycling and therefore cell contraction. Fryer et al. (1995) demonstrated that increased 
Pj might depress SR Ca2+ release in initial experiments on skinned fibers with intact 
transverse-tubular SR systems. Eberstein and Sandow (1963) reported that a fatigued 
muscle showed substantial recovery when K+ or caffeine were applied, both o f which 
are known to increase the SR Ca2+ release. They fatigued intact muscles with repeated 
tetani until force was greatly reduced. They showed that by increasing extracellular 
K+ or caffeine muscular force was substantially increased in the fatigued muscle, 
suggesting that a reversible failure o f activation was an important contributor to 
fatigue. Caffeine acts to increase the opening o f the SR Ca2+ release channels to 
overcome fatigue, thus the partial failure o f SR Ca2+ release is accepted to be one o f  
the causes o f muscle fatigue (Williams and Klug, 1995; Allen et a l ,  1995; Favero, 
1999). It is possible that PS can act in such a way as to increase Ca2+ release or
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9 +availability in a similar way to caffeine. PS has been shown to increase total Ca 
uptake in rat brain synaptosomes (Floreani et al., 1991) though incorporation o f  PS 
vesicles into rat brain. If this is the case in human cell and more Ca2+ is made 
available or more is released during exercise then PS may act in such a way to allow 
more Ca to be made available when the myofibril and therefore prolonged cross­
bridge cycling and delay the onset o f  fatigue.
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3 M ethods
3.1 Subjects
Fourteen active healthy male volunteers completed all the requirements o f  the study 
and were included in the subsequent analysis (Table 3.1). All subjects provided 
written consent for this study (Appendix 1), which was approved by a University o f 
Wales Swansea ethics committee (Appendix 2). Subjects were initially assessed for 
eligibility for the study by interview and questionnaire (Appendix 3). The subjects 
were considered eligible for the study if  they: (1) agreed to attend the laboratory when 
required; (2) had not taken nutritional supplements or medication for at least 4 weeks 
prior to testing; (3) agreed to abstain from ingesting caffeine 24 hours prior to testing; 
and (4) agreed to refrain from partaking in any additional exercise 24 hours prior to 
testing. Subjects were also made aware that they could withdraw from the study at 
any time without providing a specific explanation.
3.2 Experimental Design
A schematic diagram o f the main experimental design is presented in Figure 3.1. 
During the experimental period each subject attended the laboratory on 6 separate 
occasions over a period o f 42 ± 4 days.
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Table 3.1 Physical characteristics o f subjects that completed all study 
requirements
Physical Characteristics PS Placebo
Age (dec.years) 23.4 ± 1.9 22.2 ± 1.1
Mass (kg) 84.9 ± 3 .9 87.7 ± 3 .2
Height (m) 1.79 ±0.01 1.81 ± 0 .02
Values are mean ± SEM (N=7). PS: phosphatidylserine group; P: placebo group.
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During the initial session each subject completed preliminary assessments that 
consisted o f anthropometric measurements and an incremental exercise test. 
Following a familiarisation session that consisted o f the main trial exercise protocol 
(completed 7 ± 2 days after the preliminary assessments), each subject completed two 
main exercise trials separated by 15 ± 1 days. The main trial exercise protocol 
required the subjects to complete three 10-min stages o f cycling followed by a final 
exercise bout that was continued until volitional fatigue. Breath-by-breath respiratory 
data and heart rate data were continually recorded during both main trials. Blood 
samples and the Exercise Induced Feeling Inventory (EFI) (Gauvin and Rejeski, 
1993) were collected at pre-exercise (pre-ex), after each exercise bout and on the day 
following the main trial.
For the ten days prior to undertaking the second main trial the subjects received either 
750 mg day'1 S-PS (Appendix 5) or placebo capsule, which was similar in size and 
shape containing less than lg  o f glucose powder. Dietary records were completed for 
the three days prior to the first main exercise trial and the subjects were requested to 
match their dietary intake as closely as possible prior to the second main trial.
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3.3 Preliminary Procedures
3 . 3 . 1  Anthropometric Measurements
Body mass was determined using balanced beam scales (Seca 710; Vogel and Halke 
GmbH and Co., Germany) when subjects were dressed in minimal clothing (recorded 
to the nearest 0.1 kg) and height was measured (recorded to the nearest 1 cm) using a 
portable stadiometer (Harpenden stadiometer; Holtain Ltd, Wales) whilst the heals 
were flat against the back board and the head was supported in the Frankfurt plane.
3 . 3 . 2  Measurement of Maximal Oxygen Uptake ( V  0 2 m a x )
Subjects underwent an incremental exercise test to volitional exhaustion on an 
electronically braked cycle ergometer (Lode Excalibur Sport; Lode, Netherlands) 
which was carried out to measure maximal oxygen uptake ( V 0 2 max)> from this the 
relative intensities for the main trial’s exercise protocol were calculated.
Expired gases were analysed using an automated online gas analyser (Jaeger Oxycon 
pro; Erich Jaeger GmbH, Germany). The integrated gas analysers were calibrated 
before each test in accordance with manufactures instructions using a gas cylinder 
with known gasses (5.18% carbon dioxide in a nitrogen balance: (3 certified gas; BOC, 
UK) and a reference gas (room air). Flow rates were measured using a Triple V bi­
directional turbine which was calibrated before each test using 2 reference flow rates
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and weekly using a 3-litre syringe (Hans Rudolph, Canada), with a range o f  different 
flow rate profiles.
After the subjects were seated for at least 10 min on the cycle ergometer, resting 
respiratory data were recorded for 3 min whilst the subjects remained seated and in an 
upright position. This was followed by a 3-min warm-up at a work rate o f 60 W and a 
subsequent 2-min pre-test rest period. The incremental test began at 60 W and 
increased in work rate by 30 W every 2 min until volitional fatigue or until the subject 
could no longer maintain a pedal cadence o f at least 50 revm in'1. Breath-by-breath 
respiratory data and heart rates were recorded in 5-s intervals using short-range 
telemetry (Polar S810; Polar electro, Finland) throughout the protocol. Ratings o f  
perceived exertion (RPE) were recorded immediately following each stage.
Oxygen uptake ( V O2) data were averaged to 10-s intervals and maximum oxygen 
uptake ( V 02max) was determined as the peak V 02max recorded during exercise. All 
subjects were required to reach at least 3 out o f the 4 following criteria: (1) RPEma* 
18; (2) maximum recorded heart rate was greater than 90% o f age predicted 
maximum (220-age) (Vanderburgh and Katch, 1996); (3) respiratory exchange ratio 
(RER) 1.10 (Londeree et al., 1995); (4) change in V 02max 2.0 ml kg'1 min'1 
during the last min o f exercise (Vanderburgh and Katch, 1996).
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The average V O2 for the final 30-s period at each completed exercise stage was 
plotted against the respective work rate and the best fit linear relationship was 
determined for each subject. Subsequently, these individualised linear relationships 
and V Chmax values were used to calculate the exercise intensities for each stage o f the 
main trial exercise protocol.
3.4 Main Trial Procedures
The subjects completed both main trials at approximately the same time (± 1 hour) o f  
the day. The subjects were required to confirm that they had reported to the laboratory 
having: (1) not ingested caffeine within 24 hours; and (2) refrained from partaking in 
any additional exercise within 24 hours.
Figure 3.2 presents a schematic o f the events completed during the main trials. On 
arrival to the laboratory the subjects were required to complete a pre-ex EFI, which 
required the subjects to rate 12 different feeling states, using a 5-point likert scale 
(Gauvin and Rejeski, 1993) (Appendix 4). Subsequently, a pre-ex venous blood 
sample was taken 20 min prior to the start o f exercise. Sitting on a medical table, with 
the backboard in an upright position for approximately 10 min, a tourniquet was 
placed on the upper arm and a 21 gauge precision needle (Becton Dickinson 
Vacutainer Systems, UK) was inserted into an antecubital vein. Subsequently, two 3.5 
ml serum separation tubes (SST) (Becton Dickinson Vacutainer systems, UK) and one
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7 ml ethylenediaminetetraacetic acid (EDTA) tube (Becton Dickinson Vacutainer 
systems, UK) were filled with venous blood.
After the subjects were seated for at least 10 min on the cycle ergometer (Lode 
Excalibur Sport; Lode, Netherlands) resting respiratory data were recorded for 3 min 
whilst the subjects remained seated and in an upright position on the cycle ergometer. 
This was followed by a 3-min warm-up undertaken at the work rate o f 60 W and a 
subsequent 2-min rest period. The subjects then completed three 10-min stages o f  
cycling at approximately 45, 55 and 65% V 02max (bouts 1-3, respectively). The 
exercise bouts were interspaced with 5-min passive rest periods. Directly after the 
completion o f  the 2nd and 3rd bouts o f exercise EFI were completed and venous blood 
samples were taken whilst the subjects were seated upright on the cycle ergometer 
using the same procedures as previously described. This was followed by a final 
exercise bout at 85% V C^ max (bout 4) that was continued until volitional fatigue or 
until the subject could no longer maintain a pedal cadence o f  at least 50 rev-min'1, the 
time o f which was defined as time to exhaustion (TTE) and used as a measure o f  
exercise capacity. Breath-by-breath respiratory data were continuously recorded 
throughout the protocol (Jaeger Oxycon pro; Erich Jaeger GmbH, Germany). 
Immediately after bout 4 an end o f exercise capillary blood sample (end-ex) was 
collected whilst the subject remained upright on the cycle ergometer. Accu-Check 
Softclix Pro and lancets (Roche diagnostics GmbH, Germany) were used to collect 
approximately 50 pi o f blood in a heparinised capillary tube from the index finger. 
Subjects remained seated in an upright position on the cycle ergometer for a rest
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period o f 20 min. Directly after this a post-exercise (post-ex) resting venous blood 
samples and EFI were completed with the subjects sitting on the medical table, as 
previously described.
Approximately 24 hours after both the main trials each subject reported to the 
laboratory having fasted for at least 4 hours and resting EFI and venous blood samples 
were obtained (24-post).
3.5 Supplementation
The subjects were matched in terms o f body mass and V C^ max values and 
subsequently, they were randomly assigned, in a double-blind manner, to receive 
either S-PS (PS) or a matched glucose placebo which was similar in size and shape 
containing less than lg  o f glucose powder (placebo).
The supplement used in the present study is one marketed by Lucas Mayer. The 
method used by Lucas Meyer to produce this supplement is one o f transerterification 
o f soybean lecithin and gives a total PS concentration o f 46 to 54% in each capsule.
The PS group received 750 mg-day'1 S-PS administered in ten 75 mg S-PS capsules 
placed in generic packages to maintain double blind procedure. The placebo group 
received ten capsules filled with glucose powder. Subjects were required to take all 
the capsules with a pint o f water first thing in the morning with food. Subjects were
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supplemented for 10 days prior to undertaking the second main trial which included 
the day before attending the laboratory. Subjects were asked if  they had taken all 
supplements prior to trial 2.
3.6 Blood Analysis
Venous blood was immediately drawn from the EDTA vacutainer to measure blood 
haemoglobin concentrations in duplicate and blood lactate, glucose concentrations 
and haematocrit in triplicate. The capillary blood samples were analysed in duplicate 
for glucose and lactate concentrations. The SST tubes were allowed to coagulate for 
30 min and then centrifuged for 15 min at 3000 rpm (Labofuge 200; Kendro, 
Germany). Approximately 500 pi o f serum was then placed in an eppendorf and 
frozen at -70°C for subsequent cortisol analysis.
3.6.1 Plasma Volume
Changes in plasma volume were calculated for each individual from the pre-ex values 
in trial one using haemoglobin and haematocrit values as previously described by Dill 
and Costill (1974).
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(a) Haemoglobin
Haemoglobin was determined for each sample using an automated 2-wavelength 
photometer (570nm and 880nm) (Hemocue; Hemocue AB, Sweden) as described by 
the manufacturers instructions. The photometer was calibrated prior to each test using 
a micocuvette o f  known absorbance.
(b) Haematocrit
Heparinised capillary tubes were filled with whole blood (50-70 pi) and centrifuged 
for 5 min at 12000 rpm (Micro Haematocrit mk IV, Hawksley & Sons LTD, 
England). A microhaematocrit reader was then used to determine the haematocrit 
(Hawksley and Sons, England).
3.6.2 Serum Cortisol Concentration
Serum cortisol concentrations were determined using an automated time-resolved 
fluoroimmunoassay (AutoDELFIA™ Cortisol kit, Perkin Elmer, Life Sciences, UK). 
The dissociation enhanced lanthanide fluoroimmunoassay is based on time-resolved 
fluorescence lanthanide chemistry, where the Europium label is detected by excitation 
at 340 nm and emission at 615 nm.
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3.6.3 Glucose and Lactate
Approximately 25 pi o f whole blood was used to determine glucose and lactate 
concentrations using an automated immobilised enzyme analyser (YSI 2300D stat 
plus; YSI Incorporated, USA) as described by the manufactures instructions. The 
assays are based on the following principle:
Reaction 1 (glucose): P-D-glucose + O2 — G O x — ► Glucono-5-lactone + H2O2 
Reaction 2: H2O2 — Pt anode—► 2H+ + O2 + 2e‘
3.7 Gas and Heart Rate Analysis
Average last min oxygen uptake ( V O2) and carbon dioxide ( V CO2) 
for bouts 1 to 3 from breath-by-breath data. Last min heart rate data 
for all exercise bouts from 5-s interval data. Rates o f fuel utilisation 
using indirect calorimetry as described in (McArdle et al., 2001).
3.8 Statistical Analysis
Statistical analysis was carried out using SPSS software (version 11.0; SPSS Inc., IL). 
Group values were expressed as mean ± standard error o f the mean (SEM). Subject
were calculated 
were calculated 
were calculated
51
characteristics, environmental conditions, and V C>2max values were compared using an 
independent samples t-test. Mixed model analysis o f  variance (ANOVA) with 
repeated measures were used to determine if  differences existed between treatment 
(PS and placebo), trial (trial 1 and trial 2) or timing (stage during each trial). 
Statistical significance was accepted at the (p<0.05) level. Where significant timing 
effects or interactions including timing were identified, repeated measure ANOVA  
followed by Bonferroni pairwise comparisons were used to identify the location o f  
these differences. Where significant trial effects or interactions including trial effects 
were identified paired sample /-tests were completed to locate these differences. 
Where significant treatment effects or interactions including treatments were 
identified independent /-tests were carried out as post-hoc analyses.
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4 R esu lts
4.1 Subject Characteristics
The physical characteristics o f the subjects were similar for both treatment groups 
(Table 3.1). No significant differences in mass (.P=0.629), height (P=0.525) and age 
(P=0.644) were identified between placebo and PS.
4 . 1 . 1  Measured Maximal Oxygen Uptake ( V  0 2 m a x )
Maximum oxygen uptake for placebo and PS were 42.4 ± 1 .7  and 43.9 ± 2.3 m lkg' 
'•min'1, respectively. There were no differences in maximal oxygen uptake between 
PS and placebo (P=0.645).
4.1.2 Dietary Analysis
The total energy intake for the three days prior to each main exercise trial were 
similar between trials (P=0.493) and treatment groups (P=0.384). The total energy 
intake prior to trial 1 and trial 2 were 10285 ± 1198 and 10548 ± 1164 KJ, 
respectively for PS and 12287 ± 1387 and 11557 ± 983 KJ, respectively for placebo. 
There were no significant differences in the percentage energy intake from protein, fat
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and carbohydrate between trials (P=0.296, P=0.377 and P=0.557, respectively) or 
treatments (7^=0.214, P=0.919 and P=0.614, respectively).
4.2 Environmental Conditions During the Main Exercise Trials
4.2.1 Temperature
The ambient laboratory temperatures during the main exercise trials were similar 
between trials (P=0.765) and treatment groups (P=0.930). The ambient temperatures 
during trial 1 and trial 2 were 21.7 ± 0.6 and 21.4 ± 0.5 C, respectively for PS and 
21.3 ± 0.6 and 21.7 ± 0.6 C, respectively for placebo.
4.2.2 Barometric Pressure
The laboratory barometric pressures during the main trials were similar between trials 
(P=0.346) and treatment groups (P=0.396). The barometric pressure during trial 1 and 
trial 2 were 763.1 ± 0 .2  and 763.7 ± 0.4 mmHg, respectively for PS and 763.2 ± 0.2 
and 763.1 ± 0.2 mmHg, respectively for placebo.
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4.3 Relative Intensities, Work Rates and Heart Rate during the Main 
Exercise Trials
The mean relative oxygen consumption during the main trials were 47.0 ± 0.5, 57.7 ± 
0.5 and 69.3 ± 0.6% V 02max for the first 3 bouts o f exercise, respectively (Table 4.1). 
The trial * timing * treatment interaction was non-significant (P=0.388). There were 
no significant differences between trials (P=0.25) or treatments (P=0.22). The 
corresponding work rates for the first three bouts o f exercise were 91.3 ± 8.5, 127.4 ±
9.1 and 163.5 ± 9.9 W for PS and 90.5 ± 4.7, 124.8 ± 4.6 and 159.1 ± 4.6 W for 
placebo. During bout 4 the work rates were 235.7 ± 11.7 W for PS and 227.7 ± 5 .1  W 
for placebo. The timing * treatment interaction was not significant (P=0.456). There 
were no significant differences between treatment groups for work rate (P=0.52). 
Average last min heart rate data for the 4 bouts o f exercise were 117.9 ±3.2, 133.8 ± 
3.1, 149.9 ± 3 .5  and 180.9 ± 2 .2  beats min'1 for PS and 120.3 ± 3 .4 , 139.9 ± 4 .1 , 159.0 
± 3 .8  and 185.2 ± 2.5 beats min'1 for placebo. There were no significant differences 
between trials (P=0.59) or treatments (P=0.31).
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Table 4.1 Relative intensity o f exercise (% V 02max) achieved during the first 
three bouts o f exercise during the main trials exercise protocol for 
phosphatidylserine supplementation group (PS) and placebo group.
Relative intensities of exercise (% F 02max)
Trial Bout 1 Bout 2 Bout 3
PS Trial 1 46.9 ± 0 .1 58.4 ± 0 .8* 68.9 ± 1.6**
Placebo Trial 1 47.4 ± 0 .1 58.5 ± 0 .8* 70.9 ± 1.0*$
PS Trial 2 46.3 ± 1.4 58.4 ± 1.0* 68.9 ± 1.6*$
Placebo Trial 2 47.7 ± 1.0 58.3 ± 0 .8* 69.7 ± 1.1 *$
Values are mean ± SEM (N=7). PS: phosphatidylserine group. 
* Significant differences from bout 1 (P<0.05)
$ Significant differences from bout 2 (P<0.05)
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4.4 Exercise Capacity -  Times to Exhaustion (TTE)
The TTE were not significantly different between the supplementation groups prior to 
supplementation {P=0.87). TTE for PS and placebo were 7.9 ± 1 .6  and 8.2 ± 0.9 dec. 
min, respectively. TTE were similar between trials (P=0.61) for placebo. However, 
the times to exhaustion for PS during trial 2 (9.9 ± 1 .7  dec. min) were 25 ± 6% longer 
than trial 1 (Figure 4.1) with the trial * treatment interaction being P=0.002.
4.5 Exercise Induced Feeling Inventory
There were no significant differences in the physical exhaustion, positive engagement, 
tranquillity and revitalisation subscales between trials (P=0.249, .P=0.863, P=0.814 
and P=0.246 respectively), treatments (P=0.661, P=0.465, P=0.922 and P=0.867, 
respectively) or the trial * timing * treatment interaction (P=0.462, P=0.825, P=0.236 
and P=0.533, respectively) (Table 4.2, 4.3, 4 .4 ,4 .5  respectively).
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Figure 4.1 Exercise capacity during bout 4 o f the main trials exercise protocol.
Values represent mean ± SEM (N=7). PS: phosphatidylserine group. 
* Trial 2 significantly different from trial 1 for PS group fP<0.01).
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4.6 Blood Analysis
4.6.1 Changes in Plasma Volume
Throughout the investigation there were no significant differences in the calculated 
plasma volume changes between treatment groups (P=0.825) or by trial (P=0.427) 
(Table 4.6). During trial 1 the plasma volume was increased by 4.9 ± 2.5% for the PS 
group and 4.5 ± 1.4% for the placebo group 24 hours post-ex. During trial 2 a 3.8 ±  
2.3% increase for PS and 3.3 ± 2.2% for placebo was calculated at 24 hours post-ex. 
The trial * timing * treatment interaction was non-significant (P=0.430). There was 
no significant difference in the pre-ex plasma volume for trial 2 when compared with 
the trial 1 pre-ex values for both PS and placebo, which increased by 3.5 ± 2.7 and 0.5 
±2.1% , respectively.
4.6.2 Blood Lactate Concentration
There were no significant differences in blood lactate concentrations between trials 
(P=0.62) or between treatments (P=0.10) (Table 4.7). The trial * timing * treatment 
interaction was non-significant (P= 0.122). Blood lactate concentrations remained 
below 4 mmol L'1 for all trials during bout 2 and bout 3. The blood lactate
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concentrations at bout 4 during trial 1 and trial 2 were 7.22 ± 0.81 and 8.47 ± 0.86 
mmol L'1, respectively for PS and 8.01 ± 0.45 and 7.02 ± 0.50 mmol L'1, respectively 
for placebo (Figure 4.2). All bout 4 blood lactate values were significantly elevated 
from the pre-ex values (P<0.05).
4.6.3 Blood Glucose Concentration
Blood glucose concentrations during the main exercise trials are shown in Table 4.8. 
There were no significant differences by trial (P=0.291) or by treatment (P=0.211) 
during the main exercise trials. The trial * timing * treatment interaction was non­
significant (P=0.372). Pre-ex values o f blood glucose during the main exercise trials 
were 4.20 ± 0 .11  for PS and 4.33 ± 0.14 mmol L'1 for placebo. Post-ex values were 
4.12 ± 0.09 for PS and 4.38 ± 0.17 mmol L’1 for placebo. Blood glucose 
concentrations did not significantly change over the timing o f the trials (P=0.310).
4.6.4 Serum Cortisol Concentration
Serum cortisol concentrations during the main exercise trials are presented in Table
4.9. The trial * timing * treatment interaction was non-significant (P=0.189). There 
were no significant differences in treatment groups for the pre-ex serum cortisol 
concentrations during trial 1 (P=0.554). The peak serum cortisol concentrations at 20 
min post-ex for trial 1 and trial 2 were 626.6 ± 79.5 and 599.3 ± 50.5 nmol L'1, 
respectively for PS and 492.4 ± 61 .4  and 498.9 ± 38.2 nmol L'1, respectively for
66
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Figure 4.2 Blood lactate concentration. Values represent mean ± SEM (N=7). PS: 
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placebo. Cortisol concentrations then decreased 24 hours post-ex in both treatment 
groups and trials. Cortisol concentrations decreased to 267.6 ± 27.6 and 263.7 ± 32.9 
nmol L'1 in trial 1 and trial 2 respectively for PS and 285.3 ± 44.4 and 326.0 ± 36.7 
nmol L'1 in placebo.
4.7 Oxygen Uptake
Average last min V O2 data during both main exercise trials are presented in Table
4.10. There were no significant differences between trials (P=0.57) and treatment 
groups (P=0.48 ). The trial * timing * treatment interaction was non-significant 
(P=0.273). The mean oxygen uptake for the first 3 bouts o f exercise during the main 
exercise trials were 1.72 ± 0.07, 2.11 ± 0.09 and 2.52 ± 0.09 1 min'1 for PS and 1.75 ± 
0.04, 2.22 ± 0.06 and 2.48 ± 0.08 1 min'1 for placebo.
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Table 4.10 Oxygen uptake (V  O2) data during both exercise trials for 
phosphatidylserine supplementation group (PS) and placebo group.
Oxygen Uptake (L-min'1)
Trial Bout 1 Bout 2 Bout 3
PS Trial 1 1.73 ±0.11 2.16 ± 0 .13* 2.54 ± 0.15**
placebo Trial 1 1.74 ± 0 .05 2.22 ± 0.09 2.52 ± 0.12*$
PS Trial 2 1.71 ±  0.11 2.05 ± 0 .13* 2.50 ± 0.12*$
placebo Trial 2 1.76 ± 0 .0 6 2.22 ± 0 .1 0 2.45 ± 0.13*$
Values are mean ± SEM (N=7). PS: phosphatidylserine group. 
* Significant differences from bout 1 (P<0.05)
$ Significant differences from bout 2 (P<0.05)
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4.8 Calculated Rate of Substrate Utilisation
4.8.1 Rate of Fat Utilisation
The rate o f fat utilisation did not significantly differ during the timing o f the trials 
(P=0.84) (Table 4.11). There were no significant differences by treatment (P=0.91) 
or by trial (P=0.52). The Trial * timing * treatment interaction was not significant 
(P=0.187). The rate o f fat utilisation for the first three bouts o f exercise during the 
main exercise trials were 0.28 ± 0.03, 0.28 ± 0.04 and 0.28 ± 0.04 g min'1 for PS and 
0.28 ± 0.03, 0.26 ± 0.03 and 0.26 ± 0.03 g min'1 for placebo.
4.8.2 Rate of Carbohydrate Utilisation
The calculated rates o f carbohydrate utilisation during the main exercise trials are 
shown in Table 4.12. Carbohydrate utilisation during bout 2 were increased 45% for 
PS and 40% for placebo from bout 1 during trial 1 and increased 23% and 27% for PS 
and placebo respectively from bout 2 to bout 3. During trial 2 carbohydrate utilisation 
increased 34% and 30% from bout 1 to bout 2 for PS and placebo respectively and 
increased 32% and 27% from bout 2 to bout 3 for PS and placebo respectively. The 
trial * timing * treatment interaction was not significant (P=0.596). There were no 
significant differences between trials (P=0.41) and treatment groups (P=0.59 ).
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Table 4.11 Calculated rates o f fat utilisation during both exercise trials for 
phosphatidylserine supplementation group (PS) and placebo group.
Rate of Fat Utilisation (g min'1)
Trial Bout 1 Bout 2 Bout 3
PS Trial 1 0.28 ± 0.04 0.31 ± 0 .05 0.32 ± 0 .06
placebo Trial 1 0.30 ± 0 .02 0.27 ± 0 .04 0.28 ± 0.04
PS Trial 2 0.28 ± 0.04 0.26 ± 0.07 0.24 ± 0 .04
placebo Trial 2 0.26 ± 0.05 0.26 ± 0.05 0.24 ± 0.04
Values are mean ± SEM (N=7). PS: phosphatidylserine group.
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Table 4.12 Calculated rates o f carbohydrate utilisation during both exercise trials 
for phosphatidylserine supplementation group (PS) and placebo group.
Rate of Carbohydrate Utilisation (g min'1)
Trial Bout 1 Bout 2 Bout 3
PS Trial 1 1.29 ±0.11 1.88 ± 0.15* 2.31 ± 0.15**
placebo Trial 1 1.39 ± 0 .10 1.95 ± 0.11 * 2.49 ± 0.14*$
PS Trial 2 1.39 ± 0 .08 1.87 ± 0 .1 0 * 2.54 ± 0.12*$
placebo Trial 2 1.53 ± 0.16 1.98 ± 0.15* 2.61 ± 0.18*$
Values are mean ± SEM (N=7). PS: phosphatidylserine group. 
* Significant differences from bout 1 (P<0.05).
$ Significant differences from bout 2 (.P<0.05).
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5 D iscussion
The main findings o f the present study revealed that chronic supplementation with PS 
(750 mg-day'1 S-PS for 10 days) administered to previously familiarised subjects 
significantly increased time to exhaustion during trial 2 when compared with trial 1, 
while the placebo group showed no significant changes; although, supplementation 
had no effect on cortisol concentrations or feeling states throughout the protocol.
There were no differences in time to exhaustion (TTE) between treatment groups 
prior to supplementation. This finding confirmed that the exercise capacity o f both 
groups were similar prior to supplementation. During the present study TTE were 7.9 
± 1.6 and 8.2 ± 0.9 dec. min for PS and placebo, respectively during trial 1 and 9.9 ±  
1.7 and 8.0 ± 0.9 dec. min for PS and placebo, respectively during trial 2. These 
exercise times are in general agreement with Bell et al. (1998), who reported TTE 
values o f 12.6 ±3. 1 (S.D) min when subjects were exercising on a cycle ergometer at 
intensities o f approximately 85% V Cbmax- Numerous mechanisms have been 
suggested to cause fatigue during exercise. Generally, fatigue during endurance 
exercise has been proposed to be caused by both central and peripheral components 
(Fitts, 1996), whereas short-term intense exercise is most likely to be associated with 
peripheral mechanisms (Westerblad et al., 1991; Fitts, 1996). Peripheral fatigue might 
occur at a number o f sites during the excitation contraction coupling process, these 
include: (1) a reduction in neurotransmitter release at the neuromuscular junction
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(Davis and Bailey, 1997); (2) disturbances in the ionic changes that may lead to an 
inability to maintain the membrane potential and excitability (Green, 1997); and (3) a 
failure o f normal calcium release from the sarcoplasmic reticulum (Allen and 
Westerblad, 2001). Therefore, during the final bout o f exercise in the present exercise 
protocol, fatigue may have occurred at a number o f plausible sites.
Interestingly, TTE for the PS group during trial 2 were 25 ± 6% longer than trial 1 
(P<0.01). No previously published data has evaluated the effects o f PS 
supplementation on exercise capacity or performance; therefore, this is a novel 
finding. Although the cause o f fatigue and the mechanism(s) responsible for 
prolonging exercise after PS supplementation were not clearly identifiable, exogenous 
PS may have enhanced biochemical function at a number o f the previously implicated 
sites o f fatigue.
Acetylcholine (ACh) release has been shown to be impaired during exercise (Davis 
and Bailey, 1997). The reduction in ACh has the potential to lead to a failure in the 
activation o f the action potential and thus fatigue at an organism level. Administration 
o f PS liposomes (75-150 mg-kg'1 intraperitoneally (i.p.)) has been shown to stimulate 
cortical ACh release in both young and aged anaesthetised rat cortical slices using the 
cortical cup technique. Also, Vannucchi et a l  (1990) reported that 15 mg-kg'1 i.p. PS 
injected daily for one week stimulated ACh release from both young and old rat 
cortical slices. Transferring these findings to the human neuromuscular junction, PS
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may have delayed the onset o f fatigue by maintaining sufficient ACh at the 
neuromuscular junction during the present study.
Repetitive activation o f excitable cells, such as skeletal muscle cells, leads to ionic 
shifts across the cell membrane (Allen, 2004). Changes in ionic balance across the 
cell membrane may prevent the propagation o f  action potentials and ultimately result 
in fatigue (Fitts, 1996). These ionic shifts result in increases in extracellular potassium 
(K+) and intracellular sodium (Na+) and comparable decreases in intracellular 
potassium and extracellular sodium. Although these transmembrane fluxes are 
normally counteracted by the Na+-K+ pump, during intense muscular stimulation the 
efficacy o f the Na+-K+ pump may be reduced; consequently, sodium and potassium 
ionic shifts are thought to transpire (Clausen and Nielsen, 1994). PS has been 
demonstrated to increase membrane bound (Na+-K+)- ATPase activity after incubation 
o f brain synaptosomes plasma membranes with PS liposomes (Tsakiris and 
Deliconstantinos, 1984). Therefore, if  a PS mediated increase in ATPase activity in 
human muscle membrane was evident, it is possible that supplementation with PS 
may have acted to sustain normal ionic balance for a longer duration and thus prolong 
TTE.
Alternatively, as a result o f calcium (Ca2+) release from the sarcoplasmic reticulum 
(SR), calcium binds to troponin C, causes an interaction between myosin and actin, 
cross-bridge cycling, and subsequently leads to muscle cell contraction. 
Consequently, it has been proposed that a failure in Ca2+ release from the SR may
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contribute to fatigue, especially during high intensity exercise (Favero, 1999). PS may 
have a role in regulating calcium uptake through passive influx, depolarisation and 
Na+and K+ exchange (Floreani et al., 1991). These authors demonstrated that when
0.1-0.3 pmol PS mg protein'1 were incorporated into rat brain synaptosomes, both 
Na+- K+ exchange activity and passive Ca2+ entry were increased. Assuming that this 
finding is transferable to human muscle cells, PS may have acted in vivo to increase 
the calcium availability in the myofibril, prolonged cross-bridge cycling and increased 
exercise capacity accordingly.
No differences were observed in serum cortisol concentrations between treatment 
groups throughout trial 1. Therefore, the subject groups had similar cortisol responses 
to intermittent exercise before supplementation. Following bout 4 the serum cortisol 
concentrations peaked in all trials. These findings are in agreement with Davies and 
Few (1973) who demonstrated that plasma cortisol concentrations increased when 
exercise intensities o f approximately 60% V 02max were exceeded. The results from 
the present study showed an attenuated cortisol response to intermittent exercise when 
compared with data from Monteleone et al. (1990) and Monteleone et al. (1992). 
These authors showed significantly increased cortisol concentrations during relatively 
low intensity exercise (-45%  HRmax). These equivocal findings probably reflect the 
training status o f the subjects in the respective studies. Active subjects, like those used 
in the current study, have been previously shown to have a lower cortisol response 
when compared with sedentary individuals exercising at equivalent absolute and 
relative exercise intensities (Luger et al., 1987).
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There present study does no show any differences in cortisol concentrations during 
trial 2 when compared to trial 1 or no differences between treatment groups in both 
trials. Previous studies have shown reductions in cortisol concentrations when 
supplemented with PS during intermittent exercise (Monteleone et al., 1990; 
Monteleone et al., 1992) and following intense resistance exercise (Fahey and Pearl, 
1998). Monteleone et al. (1992) demonstrated that supplementation with 800 m gday'1 
o f BC-PS for 10 days significantly blunted the cortisol response during intermittent 
exercise. The present study used 750 mg day'1 o f S-PS for the same time period but 
found that PS did not blunt the cortisol response during intermittent exercise. Since no 
significant increases were observed in cortisol concentrations during exercise bouts 1 - 
3 in the present study, any effects that PS may have had on cortisol during these 
points would have been difficult to detect. During the present study cortisol 
concentrations significantly increased during bout 4 o f  exercise and supplementation 
did not have any effect on cortisol concentrations at this point. Direct comparisons 
between the current study and Monteleone et al. (1990) or Monteleone et al. (1992) 
may be difficult due to the timing o f the final blood sample. Cortisol was measured 20 
mins following exercise in order to obtain peak cortisol values, whereas the previous 
studies used blood samples taken at the end o f  exercise. Furthermore, during the 
current study the final bout o f exercise was continued to volitional exhaustion; 
therefore, differences in the total work done may have concealed any differences in 
the peak cortisol concentrations recorded. Fahey and Pearl (1998) showed that the 
cortisol concentration increases that follow intense resistance training were
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significantly attenuated when these subjects were supplemented with 800 mg-day"1 of  
S-PS over a 2-week period. Subjects during the present study were supplemented with 
similar doses o f S-PS over a 10-day period; however, the type, duration and intensity 
o f exercise were not comparable between this study and previous studies carried out 
with PS.
There were no differences in blood lactate concentrations between trials, which 
indicates that subjects were working at similar intensities during all the trials. This 
was in agreement with previous work carried out by Monteleone et a l  (1992) who 
found that administration with PS did not affect blood lactate concentrations during 
physical exercise. Blood lactate concentrations remained under 4 mmol L'1 during 
bouts 2 and 3; therefore, the exercise intensity during these bouts were below the 
onset o f  blood lactate accumulation (OBLA) (Kindermann et al., 1979). Therefore, 
the majority o f energy production was sourced from aerobic mechanisms during the 
first 3 bouts o f exercise. This enabled the calculation o f non-protein substrate 
utilisation using indirect calorimetry from the last min oxygen uptake (McArdle et al., 
2001). There were no differences in substrate utilisation during all trials in the present 
study (Table 4.11, 4.12). Furthermore, there were no differences in blood glucose 
concentrations during all trials in the present study. These data were in agreement 
with previous research (Monteleone et al., 1990; Monteleone et al., 1992) and 
suggested that the changes in pre-exercise cortisol concentrations did not affect 
substrate metabolism or blood glucose concentrations.
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As with any study o f this nature the present study is not without limitations. Even 
though the sample size was sufficient to identify changes in exercise capacity, it is 
possible that a larger sample size might have been required to identify the 
neuroendocrine effects o f this supplement in active individuals during maximal 
exercise. Therefore, it is a recommendation that future studies that employ a similar 
study design should have at least 10 subjects in each supplementation group. 
Phosphatidylserine supplements contain a range o f  other compounds (Appendix 5). 
Although PS is believed to be the main active ingredient o f the supplement, the 
present study has investigated the combined effects o f this supplement; consequently, 
care needs to be taken when interpreting these findings. Plausible mechanisms have 
been identified to explain why fatigue was delayed during this study; however, these 
mechanisms are speculative and future research is required to determine the 
biochemical actions o f PS that led to the current findings.
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5.1 Summary and Conclusions
Chronic supplementation with PS significantly increased times to exhaustion by 25 ± 
6%. PS supplementation did not affect serum cortisol concentrations during 
intermittent exercise. Subjects reported no differences in feeling states during exercise 
as indicated on the Exercise Induced Feeling Inventory. These data demonstrated that 
PS has the potential to delay the onset o f fatigue during intermittent exercise although 
the precise mechanism/s are unclear. Further research is required to investigate the 
mechanisms responsible for these findings.
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5.2 Future Recommendations
(1) Fatigue was delayed during a predominately anaerobic bout o f  exercise that 
was preceded by aerobic exercise. Future research could evaluate the effects o f PS 
supplementation on short-term high-intensity exercise.
(2) Evidence is presented that suggested PS delayed the onset o f fatigue; however, 
it was not possible to identify the primary mechanism(s) responsible for this finding. 
Therefore, direct and/or indirect biochemical markers could be monitored in order to 
quantify mechanisms such as ATPase activity and trans-membrane ionic balances 
during exercise.
(3) Contrary to earlier studies, PS was not effective in reducing cortisol 
concentrations during exercise in this study. It was possible that the current dosing 
regime was not able to supply sufficient PS for these active individuals. 
Consequently, future studies could provide supplementation for a longer duration.
(4) PS supplementation has the potential to act on a number o f neurotransmitters 
that have been associated with psychological mood status. Central mechanisms have 
been implicated in fatigue during prolonged exercise; therefore, it would be o f interest 
to assess the effects o f PS supplementation on exercise capacity during endurance 
activities.
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Appendix
Appendix 1 Subject information sheet and written consent
Contact Details:
Mark Miller
Department o f Sports Science 
Vivian Tower
University o f  Wales Swansea, SA28PP 
Tel: 01792 295086 
MobdBBHHMl
1. Study title
Chronic phosphatidylserine (PS) supplementation and its effect on recovery following 
exercise stress.
2. Invitation paragraph
You are being asked to volunteer for this research study. It is important that before 
you decide to take part you know what it will involve. Take time to read this 
information sheet and discuss, if  you feel you need to with friends, relatives or even 
you’re G.P. If you do not understand anything please feel free to ask.
Consumers for ethics in research (CERES) publish a leaflet entitled “medical research 
and you”. This leaflet gives more information about medical research and looks at 
some questions you may wish to ask. A copy may be obtained from CERES, PO box 
1365 London N16 OBW. Thank you for reading this.
3. What is the purpose o f this study?
The study aims to investigate the effect o f chronic supplementation o f  PS on recovery 
following exercise. It has been suggested that supplementation may increase the rate 
of recovery following exercise.
4. Why have I been chosen?
All subjects are volunteers from the University o f Wales Swansea (UWS). They will 
consist o f undergraduates and graduates. Approximately 24 subjects will take part.
5. Do I have to take part?
Taking part is entirely voluntary. If you do decide to take part you will be given this 
information sheet to keep and will be asked to sign a consent form. Even if  you decide 
to take part you are free to withdraw at any time without a reason. This will not affect 
the treatment you receive.
6. What will happen to me if  I take part?
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If you decide to take part in this study you will be required to visit the exercise 
physiology laboratory four times, each visit will last approximately 1 hour. Your first 
three visits w ill take place over the space o f one to two weeks. During these visits you 
will complete preliminary tests, a familiarisation trial and the pre-supplement main 
trial. You will then be required to undertake a thirty-day oral supplementation period, 
during which time you will consume either 750 mg-day"1 o f  phosphatidylserine (PS) 
or a placebo. A placebo is a dummy treatment, which looks like the real thing but 
contains no active ingredients. You will be randomly assigned to either the PS or 
placebo group in such a way that neither yourself o f the researcher will know which 
group you are in until the end o f the study. Following the supplementation period you 
will complete the post-supplement main trial.
You will be required to complete the following:
1) Preliminary testing: Following the completion o f a health screening 
questionnaire your weight, height and body composition will be measured. 
Following this you will complete an exercise test at progressively increasing 
intensity until you are unable to continue exercising. Heart rate, perceived 
exertion and respiratory data will be monitored throughout. This assessment 
will be used to identify your maximal exercise capacity and calculate the 
intensities you will complete each main trial.
2) Familiarisation: You will undergo an intermittent exercise test on an exercise 
ergometer. The test will require you to complete five 6-min bouts o f exercise 
separated by approximately 10-min o f recovery. The work rate for the first 
exercise bout will start at a relatively low intensity and progress to a 
moderately hard intensity for the last exercise bout.
3) Main trials: During both main trials you will complete the same intermittent 
exercise test as completed during the familiarisation. Your heart rate and 
expired respiratory gas will be monitored throughout the trials. In addition, 10 
ml venous blood samples will be obtained by the means o f an indwelling 
cannula (a thin, flexible plastic tube) or venepuncture (a small hollow needle) 
inserted in a forearm vein. Blood samples will be taken prior to exercise and 
after each recovery period.
4) Additional requirements: You will be required to consume oral 
supplementation (PS; 750 mg day'1 or placebo) over a 10-day period and 
complete 3-day exercise and dietary records during the week prior to each 
main trial. You will be asked fast overnight before reporting to the laboratory.
8. What is the supplement that is being tested?
Phosphatidyl serines are naturally occurring phosphalipids predominantly found in cell 
membranes and other structures. It is considered safe to use and is currently on the 
market as a memory aid.
9. What are the effects o f  taking part?
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There are no known side effects o f the supplement, however, if  you experience any 
adverse effects please contact us straight away.
10. What are the possible disadvantages o f taking part?
The acute risks associated with exercise are very small. However, this will be further 
minimised by the health screening you will complete prior to undertaking exercise. 
There is an extremely small risk that cannulation could result in an air or plastic 
embolism, but good practice minimises this risk. The samples will be taken by trained 
staff members.
11. What are the possible benefits o f taking part?
If you receive the PS supplement it could benefit your recovery from exercise. 
Preliminary studies have shown this might be the case.
12. Will new information become available?
New information can always come to light about research areas. If this happens while 
the study is taking place you will be informed and a course o f action will be decided.
13. What happens when the research study stops?
The supplement is available on the open market if  you wish to carry on taking it.
14. Will my taking part in the study be kept confidential?
All information collected about you will be kept strictly confidential. Any information 
that is distributed by the Department o f Sports Science will only be identifiable by 
number and not name.
15. What will happen to the results o f the research study?
The results o f the study will be disseminated to the wider Sports Science and 
Psychology community. It is intended that this will be available late 2002 early 2003.
16. Who is organising the research?
The Department o f Sports Science UWS is carrying out the research in collaboration 
with the Department o f Psychology UWS.
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Contact Details:
Mark Miller
Department of Sports Science 
Vivian Tower
University of Wales Swansea, SA28PP 
Tel: 01792 295086 MobA
Chronic phosphatidylserine (PS) supplementation and its effect on 
recovery following exercise stress.
P le a s e  in i t ia l  b o x
1. I confirm that I have read and understood the information sheet dated
 / ......../  (version n u m b e r.................................... ) for the above
study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am  free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.
□
□
3. I understand that sections of any of data obtained m ay be looked
at by responsible individuals from the University of W ales Sw ansea or 
from regulatory authorities w here it is relevant to my taking part in
research. I give permission for these individuals to have access to '------ '
these records.
4. I agree to take part in the above study.
Nam e of Subject Date Signature
N am e of Person taking consent Date Signature
Researcher Date Signature
Appendix 2 Ethical Committee Proposal
Application for Ethical Approval,
Department of Psychology, University of Wales Swansea
MPhil Project in Collaboration with the 
Department of Sports Science, University of Wales Swansea
All Project students should complete this form in consultation with their project supervisor.
If your supervisor feels that the project involves any potentially controversial procedures (i.e. 
they feel that the ethical issues raised need to be considered by the Department Ethics 
Committee) then the form should be placed in the tray in the Resources Centre for consideration 
by the Departmental Ethics Committee. Further advice will then be given to you by the Ethics 
Committee via your supervisor. The completed form should be bound along with your project 
report.
Project Title: The effects o f chronic phosphatidylserine (PS) supplementation on recovery
following exercise stress.
Students Name: Mark Miller; BSc, (Wales)
Supervisor: Mike Kingsley; MSc (Lough), BPhEd (Otago), PGCE (Wales)
Collaborator: Professor David Benton; PhD
Brief description of the purpose and methods o f the project:
Aims & purpose: To investigate chronic (PS) supplementation and its ability to enhance
recovery following exercise stress.
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No. o f  participants'. Approximately twenty-four.
How and where are the participants to be recruited: Undergraduate and postgraduate 
student volunteers will be recruited.
Experimental procedure (brief details only): Chronic supplementation o f  (PS) will take 
place. Subjects will be allocated by a placebo controlled double blind procedure. 
Preliminary testing o f subjects will include anthropometric testing and a progressive 
maximal exercise test on a cycle ergometer. Subjects will then undergo a familiarisation 
trail followed by 2 trials (pre and post supplementation). The exercise administration will 
be in the form o f a repeated progressive exercise and recovery on a cycle ergometer. 
Measurement procedures will consist o f heart rate monitoring, venous blood samples, 
respiratory gas analysis and other non-invasive procedures. A full description o f the study 
design is attached (Appendix A).
Details o f  any payment given: None
Consent and Debriefing
Have you prepared a consent form for participants? YES (Appendix B)
Have you prepared an information sheet to debrief participants? YES (Appendix C)
You must attach the consent form and information sheet before handing this 
form to your supervisor. You must also attach a copy o f any questionnaire(s) 
that you intend using.
Ethical Considerations
Please read the following declarations carefully and detail below any ways in which 
your project deviates from them. Then sign where indicated.
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1. I have ensured that there will be no active deception o f  participants.
2. I have ensured that no data will be personally identifiable.
3. I have ensured that no participant should suffer any undue physical or psychological 
discomfort
4. I certify that there will be no administration o f potentially harmful drugs, medicines or 
foodstuffs. *
5. I will obtain written permission from an appropriate authority before recruiting 
members o f any outside institution as participants.
6. I certify that the participants will not experience any potentially unpleasant stimulation 
or deprivation?
7. I certify that any ethical considerations raised by this proposal have been discussed in 
detail with my supervisor.
8. I certify that the above statements are true with the following exception(s):
* (4)- See appendix D
Students signature: Date:
In the supervisor’s opinion, this project (tick one only):
Does not raise any significant issues.
Raises some ethical issues, but I consider that appropriate steps and precautions have been 
taken and I have approved the proposal and accept the responsibility for having done so. 
Raises ethical issues that need to be considered by the Departmental Ethics Committee. 
Raises ethical issues such that it should not be allowed to proceed in its current form.
Supervisor’s signature: Date:
(For Ethics Committee use only)
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The ethical issues raised by this project have been considered by members o f the Departmental 
Ethics Committee who made the following comments:
Please ensure that you take account o f these comments and prepare a revised submission that 
should be shown to your supervisor/ resubmitted to the Department Ethics Committee (delete as
appropriate).
Signed: Date:
(Chair, Departmental Ethics Committee)
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Appendix 3 Subject information checklist
This is a very important study and it is very important I have subjects that are willing 
to follow the instructions presented to them. Subjects should read the information 
sheet and decide very carefully whether they wish to take part in this study or not. If 
they choose not to this decision will be respected however if  you do decide to help me 
out it is very important you follow the instructions given any deviation from these 
could result in my whole study being rendered useless. Could you please answer the 
question below honestly:
What other supplements are you currently taking if  any?
What sport or physical activity do you take part in?
On what days do you take part in these activities?
Do you follow a strict diet?
Are you willing to forgo any alcohol 24 hours before any testing?
Are you willing to take at least 10 tablets a day for 10 days?
Are you willing to give blood for samples each on 5 separate occasions?
Are you willing to come into the lab on 5 separate occasions?
Are you willing to forgo caffeine on the day o f testing?
Are you willing to write down what you have eaten 3 days prior to any testing and 
repeat this before any other testing?
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Appendix 4: Exercise-Induced Feeling Scale
Instructions: Please use the following scale to indicate the extent to which each word 
below describes how you feel at this moment in time. Record your responses by 
placing an X in the appropriate box.
0 = Do Not Feel [DNF]
1 = Feel Slightly
2 = Feel Moderately
3 = Feel Strongly
4 = Feel Very Strongly [FVS]
DNF FVS
0 1 2 3 4
1. Refreshed
2. Calm
3. Fatigued
4. Enthusiastic
5. Relaxed
6. Energetic
7. Happy
8. Tired
9. Revived
10. Peaceful
11. W orn-out
12. Upbeat
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Appendix 5: Composition of the supplement
Table 1 shows the typical composition o f the concentrated phosphatidylserine product 
as analysed by an independent consulting company. The remaining content will 
reflect the composition o f the source soybean lecithin. Lecithin is usually used as a 
synonym for phosphatidylcholine, although the composition o f lecithin is variable 
depending upon the source soybean. However, soybean lecithin also contains, to a 
lesser extent, a mixture o f phospholipids, tocopherols, triglycerides, and free fatty 
acids. The approximate content o f the final product (from commercial analysis) is 
listed in Table 2.
Table 1: Typical composition o f concentrated phosphatidylserine product.
Phospholipids Composition
Phosphatidylserine 45-54%
Phosphatidylcholine 5-7%
Phosphatidylethanolamine 6-10%
Phosphatidylinositol 1-3%
Phosphatidic acid 4-7%
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Table 2: Approximate composition o f  final phosphatidylserine product.
Phospholipids Composition
Phosphatidylserine 20%
Phosphatidylcholine 9%
Phosphatidylethanolamine 2%
Phosphatidylinositol 2%
Linoleic Acid 23%
Linolenic Acid 2%
Oleic Acid 2%
Stearic Acid <1%
Palmitic Acid 5%
Capric Acid 10%
Caprylic Acid 26%
Phosphorus 2%
Potassium <1%
Others (including tocopherol) Not listed
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Appendix 6 Raw data for subject characteristics and measured maximal 
oxygen uptake
Supp/Sub
Age
(dec.years)
V Cbmax 
(l/min)
V 02max 
(ml/min/kg) Mass (kg) Height (m)
PS/1 23.38 3.64 40.9 89 1.83
PS/2 20.33 3.78 44.5 85 1.77
PS/3 21.28 3.73 35.2 106 1.76
PS/4 20.25 4.64 53.3 87 1.74
PS/5 20.89 3.73 49.1 76 1.76
PS/6 36.08 2.97 43.7 68 1.84
PS/7 21.8 3.34 40.2 83 1.8
Mean 23.43 3.69 43.8 84.9 1.79
SEM 2.15 0.19 2.3 4.5 0.01
Supp/Sub
Age
(dec.years)
V Cbmax 
(l/min)
V Cbmax 
(ml/min/kg) Mass (kg) Height (m)
P/8 21.34 3.55 34.5 103 1.83
P/9 22.48 3.17 41.7 76 1.78
P/10 18.97 3.96 49.5 80 1.76
P /ll 21.04 3.86 43.4 89 1.82
P/12 19.48 3.69 38.0 97 1.93
P/13 23.47 3.89 48.0 81 1.82
P/14 28.73 3.68 41.8 88 1.7
Mean 22.21 3.69 42.4 87.7 1.81
SEM 1.24 0.10 2.0 3.7 0.03
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 8 Raw date for temperature ( C) and barometric pressure 
(mmHg) during both main trials
Supp/Sub
Trial 1 Trial 2
Temp Pressure Temp Pressure
PS/1 23 762.8 23 762.8
PS/2 23 762.8 23 762.8
PS/3 20 763.6 20 763.6
PS/4 20 763.6 20 763.6
PS/5 20 763.6 20 763.6
PS/6 23 762.8 22 763.6
PS/7 23 762.8 22 765.8
Mean 21.7 763.1 21.4 763.7
SEM 0.6 0.2 0.5 0.4
Supp/Sub
Trial 1 Trial 2
Temp Pressure Temp Pressure
P/8 20 763.6 20 763.6
P/9 20 763.6 20 763.6
P/10 23 762.8 23 762.8
P/ l l 20 763.6 23 762.8
P/12 20 763.6 20 763.6
P/13 23 762.8 23 762.8
P/14 23 762.8 23 762.8
Mean 21.3 763.2 21.7 763.1
SEM 0.6 0.2 0.6 0.2
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 9 Raw data for the mean relative oxygen consumption during 
the main trials ( % F  0 2 m a x )
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
PS/1 49.3 61.3 71.6 40.9 52.6 64.8
PS/2 50.3 61.5 64.9 45.9 54.8 72.2
PS/3 47.5 58.4 71.2 48.3 58.3 69.1
PS/4 47.5 58.2 66.9 48.7 58.5 66.9
PS/5 44.1 59.2 76.2 46.5 55.5 67.0
PS/6 46.4 55.6 66.6 51.3 57.5 70.4
PS/7 42.9 54.6 64.8 42.4 51.7 64.9
Mean 46.9 58.4 68.9 46.3 55.6 67.9
SEM 1.0 1.0 1.6 1.4 1.0 1.1
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
P/8 48.4 58.0 68.0 49.0 56.5 66.1
P/9 48.4 59.3 75.1 48.1 59.5 71.2
P/10 45.2 54.3 66.9 42.5 54.3 65.3
P/ l l 49.1 60.2 71.6 50.8 62.2 75.2
P/12 46.1 58.6 73.3 46.4 57.9 69.5
P/13 49.7 61.6 71.6 51.4 60.2 68.3
P/14 44.6 57.4 69.5 45.7 57.8 72.1
Mean 47.4 58.5 70.9 47.7 58.3 69.7
SEM 0.8 0.9 1.1 1.2 1.0 1.3
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 10 Raw data for work rate during both main trials (W)
Supp/Sub Bout 1 Bout 2 Bout 3 Bout 4
PS/1 92 128 164 235
PS/2 93 134 175 257
PS/3 79 116 154 228
PS/4 144 182 219 295
PS/5 95 133 171 246
PS/6 69 99 128 187
PS/7 67 101 134 202
Mean 91.3 127.4 163.5 235.7
SEM 9.8 10.6 11.4 13.5
Supp/Sub Bout 1 Bout 2 Bout 3 Bout 4
P/8 85 119 153 221
P/9 81 112 143 204
P/10 100 136 172 244
P/ l l 109 143 176 244
P/12 81 119 157 232
P/13 105 138 171 237
P/14 71 107 142 213
Mean 90.5 124.8 159.1 228.0
SEM 5.4 5.3 5.4 5.9
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 12 Raw data for times to exhaustion (dec.min) during 
bout 4 of exercise during both main trials
Supp/Sub
Trial 1 Trial 2
TTE TTE
PS/1 8.12 11.9
PS/2 16.25 18
PS/3 4.47 5.6
PS/4 7.32 10.4
PS/5 4.78 5.03
PS/6 4.38 7.15
PS/7 9.63 10.85
Mean 7.85 9.85
SEM 1.6 1.69
Supp/Sub
Trial 1 Trial 2
TTE TTE
P/8 12.00 12.27
P/9 9.20 8.60
P/10 5.95 6.45
P/ l l 6.97 5.95
P/12 10.35 10.03
P/13 6.02 5.97
P/14 6.53 6.95
Mean 8.15 8.03
SEM 0.90 0.91
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 29 Raw data for average last min oxygen uptake ( V  0 2 ) 
data during both main exercise trials
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
PS/1 1.8 2.23 2.61 1.49 1.92 2.36
PS/2 1.9 2.33 2.45 1.74 2.07 2.73
PS/3 1.77 2.18 2.66 1.8 2.18 2.58
PS/4 2.21 2.7 3.1 2.26 2.71 3.11
PS/5 1.65 2.21 2.84 1.74 2.07 2.5
PS/6 1.38 1.65 1.98 1.52 1.71 2.09
PS/7 1.43 1.83 2.16 1.42 1.73 2.17
Mean 1.73 2.16 2.54 1.71 2.05 2.5
SEM 0.11 0.13 0.15 0.11 0.13 0.13
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
P/8 1.72 2.06 2.41 1.74 2.01 2.35
P/9 1.54 1.88 2.38 1.52 1.89 2.26
P/10 1.79 2.15 2.65 1.68 2.15 2.59
P/ l l 1.90 2.32 2.77 1.96 2.40 2.90
P/12 1.70 2.16 2.71 1.71 2.14 2.57
P/13 1.93 2.40 2.79 2.00 2.34 2.66
P/14 1.64 2.56 1.92 1.68 2.66 1.85
Mean 1.74 2.22 2.52 1.76 2.22 2.45
SEM 0.05 0.09 0.12 0.06 0.10 0.13
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 30 Raw data for average last min carbon dioxide uptake 
( V  CO2) used in calculations for substrate utilisation 
data during both main exercise trials
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
PS/1 1.57 1.96 2.35 1.42 1.90 2.38
PS/2 1.75 2.23 2.36 1.53 1.93 2.63
PS/3 1.58 2.06 2.39 1.67 2.07 2.43
PS/4 1.96 2.44 2.81 1.98 2.39 2.86
PS/5 1.55 2.06 2.75 1.60 1.86 2.36
PS/6 1.27 1.50 1.87 1.38 1.60 2.00
PS/7 1.33 1.66 2.02 1.27 1.63 2.07
Mean 1.57 1.99 2.36 1.55 1.91 2.39
SEM 0.09 0.12 0.13 0.09 0.10 0.11
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
P/8 1.55 1.87 2.18 1.54 1.86 2.15
P/9 1.36 1.76 2.20 1.44 1.80 2.14
P/10 1.66 2.04 2.55 1.50 2.03 2.60
P/ l l 1.78 2.25 2.65 1.83 2.31 2.83
P/12 1.54 2.01 2.49 1.61 1.94 2.41
P/13 1.73 2.17 2.59 1.94 2.24 2.58
P/14 2.11 1.42 2.50 2.13 1.42 2.45
Mean 1.67 1.93 2.45 1.71 1.94 2.45
SEM 0.09 0.11 0.07 0.10 0.11 0.09
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 31 Fat utilisation during bouts 1-3 during both main 
exercise trials
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
PS/1 0.40 0.47 0.45 0.11 0.03 n/a
PS/2 0.27 0.17 0.17 0.37 0.25 0.18
PS/3 0.34 0.21 0.46 0.24 0.19 0.26
PS/4 0.43 0.47 0.52 0.49 0.58 0.43
PS/5 0.16 0.27 0.16 0.24 0.38 0.25
PS/6 0.19 0.26 0.20 0.25 0.20 0.17
PS/7 0.18 0.29 0.26 0.26 0.17 0.17
Mean 0.28 0.31 0.32 0.28 0.26 0.24
SEM 0.04 0.05 0.06 0.04 0.07 0.04
Trial 1 Trial 2
Supp/Sub Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
P/8 0.30 0.34 0.42 0.35 0.26 0.34
P/9 0.30 0.21 0.32 0.15 0.16 0.21
P/10 0.23 0.20 0.17 0.32 0.22 n/a
P/ l l 0.21 0.13 0.20 0.23 0.15 0.14
P/12 0.29 0.27 0.37 0.19 0.34 0.27
P/13 0.35 0.40 0.35 0.11 0.19 0.14
P/14 0.39 0.34 0.11 0.47 0.49 0.36
Mean 0.30 0.27 0.28 0.26 0.26 0.24
SEM 0.02 0.04 0.04 0.05 0.05 0.04
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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Appendix 32 Raw data for carbohydrate utilisation (g min'1) during 
bouts 1-3 during the main exercise trials
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
PS/1 1.20 1.56 2.07 1.52 2.24 2.93
PS/2 1.66 2.41 2.55 1.21 1.90 2.88
PS/3 1.33 2.13 2.10 1.60 2.16 2.48
PS/4 0.78 2.14 2.50 1.55 1.89 2.72
PS/5 1.60 2.02 3.05 1.52 1.59 2.42
PS/6 1.21 1.36 1.92 1.25 1.59 2.13
PS/7 1.29 1.51 1.99 1.09 1.69 2.21
Mean 1.29 1.88 2.31 1.39 1.87 2.54
SEM 0.11 0.15 0.15 0.08 0.10 0.12
Supp/Sub
Trial 1 Trial 2
Bout 1 Bout 2 Bout 3 Bout 1 Bout 2 Bout 3
P/8 1.35 1.67 1.91 1.27 1.79 2.01
P/9 1.12 1.76 2.10 1.47 1.90 2.23
P/10 1.60 2.12 2.80 1.26 2.08 3.19
P/ l l 1.78 2.50 2.86 1.81 2.53 3.18
P/12 1.35 1.95 2.37 1.81 1.77 2.45
P/13 1.50 1.93 2.54 2.15 2.38 2.88
P/14 1.05 1.73 2.83 0.91 1.40 2.34
Mean 1.39 1.95 2.49 1.53 1.98 2.61
SEM 0.10 0.11 0.14 0.16 0.15 0.18
Supp/Sub: Supplementation / Subject Number. PS: phosphatidylserine group, P: 
Placebo
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